C:\Program Files\Stnexp\Queries\10621139.str





```
ring nodes :
    1  2  3  4  5  6  7  8  9
ring bonds :
    1-2  1-6  2-3  3-4  4-5  4-7  5-6  5-9  7-8  8-9
exact/norm bonds :
    1-2  1-6  2-3  3-4  4-5  4-7  5-6  5-9  7-8  8-9
isolated ring systems :
    containing 1 :

G1:C,N

Match level :
    1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom
```

C \Program Files\Stnexp\Queries\10621139-2.str





ring nodes :
1 2 3 4 5 6 7 8 9
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9
exact/norm bonds :
5-9 8-9
exact bonds :
4-7 7-8
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

G1:C,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptaul22ebb

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	SEP 09	CA/CAplus records now contain indexing from 1907 to the present
NEWS 4	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS 5	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 6	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS 7	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS 8	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Righ Truncation
NEWS 9	AUG 18	Simultaneous left and right truncation added to ANABSTR
NEWS 10	SEP 22	DIPPR file reloaded
NEWS 11	DEC 08	INPADOC: Legal Status data reloaded
NEWS 12	SEP 29	DISSABS now available on STN
NEWS 13	OCT 10	PCTFULL: Two new display fields added
NEWS 14	OCT 21	BIOSIS file reloaded and enhanced
NEWS 15	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS 16	NOV 24	MSDS-CCOHS file reloaded
NEWS 17	DEC 08	CABA reloaded with left truncation
NEWS 18	DEC 08	IMS file names changed
NEWS 19	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS 20	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS 21	DEC 17	DGENE: Two new display fields added
NEWS 22	DEC 18	BIOTECHNO no longer updated
NEWS 23	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS 24	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS 25	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS 26	DEC 22	ABI-INFORM now available on STN

NEWS EXPRESS	DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:26:54 ON 29 DEC 2003

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:27:07 ON 29 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 DEC 2003 HIGHEST RN 631841-90-2
DICTIONARY FILE UPDATES: 28 DEC 2003 HIGHEST RN 631841-90-2

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading 10621139.str

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 12:27:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 110042 TO ITERATE

0.9% PROCESSED 1000 ITERATIONS 8 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: EXCEEDS 1000000
PROJECTED ANSWERS: EXCEEDS 15827

```
=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1993

L3    SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\10621139.str

L4      STRUCTURE UPLOADED

=> que L4 AND L3

L5   QUE L4 AND L3

=> s l5
SAMPLE SEARCH INITIATED 12:30:03 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  90861 TO ITERATE

  1.1% PROCESSED    1000 ITERATIONS                                  3 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      EXCEEDS 1000000
PROJECTED ANSWERS:         EXCEEDS    4461

L6            3 SEA SSS SAM L4 AND L3

=> d l6 1-3
```

L6 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2003 ACS on STN
RN 616205-68-6 REGISTRY
CN Cobalt, bis[[2,3-butanedione di(oximato-.kappa.N)](1-)]bis(1H-indole)-, (OC-6-12)- (9CI) (CA INDEX NAME)
MF C24 H28 Co N6 O4
CI CCS
SR CA
LC STN Files: CA, CAPLUS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L6 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2003 ACS on STN
RN 211997-65-8 REGISTRY
CN Boron, triphenyl(1H-pyrrolo[2,3-b]pyridine-.kappa.N7)-, (T-4)- (9CI) (CA INDEX NAME)
MF C25 H21 B N2
CI CCS
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L6 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2003 ACS on STN
RN 201809-04-3 REGISTRY
CN 1-Piperazinecarboxylic acid, 4-[4-[(1H-indol-5-ylamino)carbonyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C24 H28 N4 O3
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d rsd

L6 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2003 ACS on STN

Ring System Data

Elemental Analysis EA	Elemental Sequence ES	Size of the Rings SZ	Ring System Formula RF	Ring Identifier RID	RID Occurrence Count
C2CoN2-C2CoN2	CoNC2N-CoNC2N	5-5	C4CoN4	284.171.4	1
C4N-C6	NC4-C6	5-6	C8N	333.151.57	2

```
=> s nc5-nc4/es
L7              0 NC5-NC4/ES

=> s nc4-nc5/es
L8          59638 NC4-NC5/ES

=> d scan
```

L8 59638 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C25 H34 N4 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 59638 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C15 H13 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L8 59638 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C68 H72 N4 O2 S2

Relative stereochemistry.
Double bond geometry unknown.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

```
=> d his

     (FILE 'HOME' ENTERED AT 12:26:54 ON 29 DEC 2003)

     FILE 'REGISTRY' ENTERED AT 12:27:07 ON 29 DEC 2003
L1               STRUCTURE UPLOADED
L2             8 S L1
L3               SCREEN 1993
L4               STRUCTURE UPLOADED
L5               QUE L4 AND L3
L6             3 S L5
L7             0 S NC5-NC4/ES
L8         59638 S NC4-NC5/ES

=> s l1
SAMPLE SEARCH INITIATED 12:36:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 110042 TO ITERATE

  0.9% PROCESSED    1000 ITERATIONS                                 8 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **INCOMPLETE**
                        BATCH   **INCOMPLETE**
PROJECTED ITERATIONS:      EXCEEDS 1000000
PROJECTED ANSWERS:         EXCEEDS   15827

L9             8 SEA SSS SAM L1

=> del l9
DELETE L9? (Y)/N:y

=> s l1 sub=l8
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):sam
SAMPLE SUBSET SEARCH INITIATED 12:37:15 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -     973 TO ITERATE

100.0% PROCESSED     973 ITERATIONS                                36 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):          ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):      17589 TO    21331
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):           360 TO     1080

L9            36 SEA SUB=L8 SSS SAM L1

=> d his

     (FILE 'HOME' ENTERED AT 12:26:54 ON 29 DEC 2003)

     FILE 'REGISTRY' ENTERED AT 12:27:07 ON 29 DEC 2003
L1               STRUCTURE UPLOADED
L2             8 S L1
L3               SCREEN 1993
L4               STRUCTURE UPLOADED
L5               QUE L4 AND L3
L6             3 S L5
L7             0 S NC5-NC4/ES
```

```
L8         59638 S NC4-NC5/ES
L9            36 S L1  SUB=L8 SAM

=> d scan
```

L9 36 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Carbamic acid, [(4S)-6-chloro-3,4-dihydro-1,1-dioxido-7-[(1H-pyrrolo[2,3-b]pyridin-4-ylamino)carbonyl]-2H-1-benzothiopyran-4-yl]-, phenylmethyl ester (9CI)
MF C25 H21 Cl N4 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 36 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-Pyrrolo[3,2-b]pyridine, 5-(methylthio)- (9CI)
MF C8 H8 N2 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 36 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1,3-Benzenedicarboxamide, N,N'-bis(1H-pyrrolo[2,3-b]pyridin-6-yl)- (9CI)
MF C22 H16 N6 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L9 36 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-Pyrrolo[2,3-c]pyridine-7-carboxaldehyde, 4-fluoro- (9CI)
MF C8 H5 F N2 O



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

```
=> d his

     (FILE 'HOME' ENTERED AT 12:26:54 ON 29 DEC 2003)

     FILE 'REGISTRY' ENTERED AT 12:27:07 ON 29 DEC 2003
L1               STRUCTURE UPLOADED
L2             8 S L1
L3               SCREEN 1993
L4               STRUCTURE UPLOADED
L5               QUE L4 AND L3
L6             3 S L5
L7             0 S NC5-NC4/ES
L8         59638 S NC4-NC5/ES
L9            36 S L1  SUB=L8 SAM

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
G1 C,N


Structure attributes must be viewed using STN Express query preparation.


=> s l1 sub=l8
ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
FULL SUBSET SEARCH INITIATED 12:38:40 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -  19713 TO ITERATE

100.0% PROCESSED   19713 ITERATIONS                          656 ANSWERS
SEARCH TIME: 00.00.01

L10          656 SEA SUB=L8 SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                             182.63     182.84

FILE 'CAPLUS' ENTERED AT 12:38:48 ON 29 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 29 Dec 2003 VOL 140 ISS 1
FILE LAST UPDATED: 28 Dec 2003 (20031228/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l10
L11 793 L10

=> analyze l11 rn hit 1-
ANALYZE IS APPROXIMATELY 69% COMPLETE
L12 ANALYZE L11 1- RN HIT : 633 TERMS

=> d
L12 ANALYZE L11 1- RN HIT : 633 TERMS

TERM #	# OCC	# DOC	% DOC	RN
1	519	511	64.44	271-63-6
2	81	81	10.21	271-34-1
3	51	51	6.43	271-29-4
4	49	49	6.18	272-49-1
5	19	19	2.40	17288-40-3
6	16	16	2.02	55052-28-3
7	14	13	1.64	480-98-8
8	13	13	1.64	55052-24-9
9	12	12	1.51	824-24-8
10	12	11	1.39	25247-73-8

=> file reg\
'REG\' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'CAPLUS'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 10.53 193.37

FILE 'REGISTRY' ENTERED AT 12:39:55 ON 29 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

10/621139

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 DEC 2003 HIGHEST RN 631841-90-2
DICTIONARY FILE UPDATES: 28 DEC 2003 HIGHEST RN 631841-90-2

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> s 271-63-6/rn
L13 1 271-63-6/RN

=> d scan

L13 1 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI)
MF C7 H6 N2
CI COM, RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> d his

     (FILE 'HOME' ENTERED AT 12:26:54 ON 29 DEC 2003)

     FILE 'REGISTRY' ENTERED AT 12:27:07 ON 29 DEC 2003
L1                STRUCTURE UPLOADED
L2              8 S L1
L3                SCREEN 1993
L4                STRUCTURE UPLOADED
L5                QUE L4 AND L3
L6              3 S L5
L7              0 S NC5-NC4/ES
L8          59638 S NC4-NC5/ES
L9             36 S L1  SUB=L8 SAM
L10           656 S L1  SUB=L8 FUL

     FILE 'CAPLUS' ENTERED AT 12:38:48 ON 29 DEC 2003
L11           793 S L10
L12           ANALYZE L11 1- RN HIT :      633 TERMS

     FILE 'REGISTRY' ENTERED AT 12:39:55 ON 29 DEC 2003
L13             1 S 271-63-6/RN

=> s l11 not l13
L14         655 L11 NOT L13

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.40     193.77

FILE 'CAPLUS' ENTERED AT 12:40:32 ON 29 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 29 Dec 2003  VOL 140 ISS 1
FILE LAST UPDATED: 28 Dec 2003  (20031228/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> s l14
L15         419 L14

=> s l15 and l13
```

```
           511 L13
L16        137 L15 AND L13

=> s 271?/rn
TERM '271?' EXCEEDED TRUNCATION LIMITS - SEARCH ENDED
You have entered a truncated stem which occurs in too many terms.
Make the stem longer and try again.  For example, if your original
term was 'degr?' to search for variations and the abbreviation for
'degradation', you could replace it with the expression '(degrdn OR
degrad?)'.  If your search term was numeric, e.g., 'C>5', reduce the
size of the range.

=> s 271-?/rn
L17       3826 271-?/RN
                (271-?)

=> d his

     (FILE 'HOME' ENTERED AT 12:26:54 ON 29 DEC 2003)

     FILE 'REGISTRY' ENTERED AT 12:27:07 ON 29 DEC 2003
L1                STRUCTURE UPLOADED
L2              8 S L1
L3                SCREEN 1993
L4                STRUCTURE UPLOADED
L5                QUE L4 AND L3
L6              3 S L5
L7              0 S NC5-NC4/ES
L8          59638 S NC4-NC5/ES
L9             36 S L1  SUB=L8 SAM
L10           656 S L1  SUB=L8 FUL

     FILE 'CAPLUS' ENTERED AT 12:38:48 ON 29 DEC 2003
L11           793 S L10
L12           ANALYZE L11 1- RN HIT :      633 TERMS

     FILE 'REGISTRY' ENTERED AT 12:39:55 ON 29 DEC 2003
L13             1 S 271-63-6/RN
L14           655 S L11 NOT L13

     FILE 'CAPLUS' ENTERED AT 12:40:32 ON 29 DEC 2003
L15           419 S L14
L16           137 S L15 AND L13
L17          3826 S 271-?/RN

=> s l10 and l17
           793 L10
L18        578 L10 AND L17

=> del l18
DELETE L18? (Y)/N:y

=> del l17
DELETE L17? (Y)/N:y

=> file reg
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY     SESSION
```

FULL ESTIMATED COST 2.97 196.74

FILE 'REGISTRY' ENTERED AT 12:42:26 ON 29 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 DEC 2003 HIGHEST RN 631841-90-2
DICTIONARY FILE UPDATES: 28 DEC 2003 HIGHEST RN 631841-90-2

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> s 271-?/rn
L17 98 271-?/RN

=> d scan

L17 98 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 2H-Pyrazolo[3,4-c]pyridine (8CI, 9CI)
MF C6 H5 N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L17 98 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Pyrano[2,3-c]pyrazole (8CI, 9CI)
MF C6 H4 N2 O
CI RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L17 98 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 4H-Indole (8CI, 9CI)
MF C8 H7 N



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L17 98 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 6H-Pyrrolo[2,3-b]pyridine (8CI, 9CI)
MF C7 H6 N2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L17 98 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Furo[3,4-b]pyridine (8CI, 9CI)
MF C7 H5 N O
CI COM, RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L17 98 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-Indazole (7CI, 8CI, 9CI)
MF C7 H6 N2
CI COM, RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L17 98 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN Pyrano[2,3-b]pyrrole (8CI, 9CI)
MF C7 H5 N O
CI RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L17 98 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 3aH-Indole (8CI, 9CI)
MF C8 H7 N



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

```
=> d his

     (FILE 'HOME' ENTERED AT 12:26:54 ON 29 DEC 2003)

     FILE 'REGISTRY' ENTERED AT 12:27:07 ON 29 DEC 2003
L1                STRUCTURE UPLOADED
L2              8 S L1
L3                SCREEN 1993
L4                STRUCTURE UPLOADED
L5                QUE L4 AND L3
L6              3 S L5
L7              0 S NC5-NC4/ES
L8          59638 S NC4-NC5/ES
L9             36 S L1  SUB=L8 SAM
L10           656 S L1  SUB=L8 FUL

     FILE 'CAPLUS' ENTERED AT 12:38:48 ON 29 DEC 2003
L11           793 S L10
L12           ANALYZE L11 1- RN HIT :      633 TERMS

     FILE 'REGISTRY' ENTERED AT 12:39:55 ON 29 DEC 2003
L13             1 S 271-63-6/RN
L14           655 S L11 NOT L13

     FILE 'CAPLUS' ENTERED AT 12:40:32 ON 29 DEC 2003
L15           419 S L14
L16           137 S L15 AND L13

     FILE 'REGISTRY' ENTERED AT 12:42:26 ON 29 DEC 2003
L17            98 S 271-?/RN

=> s l10 and pyrrolo?
        186603 PYRROLO?
L18        606 L10 AND PYRROLO?

=> s l10 not l18
L19           50 L10 NOT L18

=> s l17 and l19
L20            0 L17 AND L19

=> del l19-
DELETE L19-L20? (Y)/N:y

=> s pyrid?
L19     1720701 PYRID?

=> s l18 and l19
L20         605 L18 AND L19

=> s l17 and l20
L21           3 L17 AND L20

=> d scan
```

L17 98 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI)
MF C7 H6 N2
CI COM, RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L17 98 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN 7H-Pyrrolo[3,4-d]pyrimidine (8CI, 9CI)
MF C6 H5 N3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

L21 3 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN **1H-Pyrrolo[3,2-c]pyridine (6CI, 7CI, 8CI, 9CI)**
MF C7 H6 N2
CI COM, RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L21 3 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN **1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI)**
MF C7 H6 N2
CI COM, RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L21 3 ANSWERS REGISTRY COPYRIGHT 2003 ACS on STN
IN **1H-Pyrrolo[2,3-c]pyridine (6CI, 7CI, 8CI, 9CI)**
MF C7 H6 N2
CI COM, RPS



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

```
=> s l20 not l21
L22         602 L20 NOT L21

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     9.64     206.38

FILE 'CAPLUS' ENTERED AT 12:44:21 ON 29 DEC 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 29 Dec 2003  VOL 140 ISS 1
FILE LAST UPDATED: 28 Dec 2003  (20031228/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.

=> s l22
L23         345 L22

=> s l21
L24         574 L21

=> s l24 and patent/dt
       4249379 PATENT/DT
L25         139 L24 AND PATENT/DT

=> s l23
L26         345 L22

=> del l26
DELETE L26? (Y)/N:y

=> s l23 and patent/dt
       4249379 PATENT/DT
L26         136 L23 AND PATENT/DT

=> s l25 and l26
L27          45 L25 AND L26     SAW
=>
=> d l27 1-45 bib abs hitstr
```

L27 ANSWER 1 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:972076 CAPLUS
TI 1-(Aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands
IN Bernotas, Ronald Charles; Lenicek, Steven Edward; Antane, Schuyler A.
PA Wyeth, John, and Brother Ltd., USA
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003101990	A1	20031211	WO 2003-US17466	20030603
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003236278	A1	20031225	US 2003-453010	20030603
PRAI	US 2002-385502P	P	20020604		

GI



I

AB The present invention provides title compds. I (W, X, Y, Z = N or substituted C; n = 2-5; R1 = C1-C6 alkyl, C3-C7 cycloalkyl, aryl etc.; R2 = H, halogen, or a C1-C6 alkyl, C1-C6 alkoxy etc.; R3, R4 = H or C1-C6 alkyl group; R5, R6 = H or C1-C6 alkyl group, C2-C6 alkenyl etc.), and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor. Thus, title compd. I (R1 = 1-naphthyl; R2 = H; Z = N; X, Y, W = C; CR3R4 = CH2CH2; R5 = R6 = Me) was prepd. (mp 203-206.degree.) and demonstrated binding to the 5-hydroxytryptamine-6 receptor with Ki value 1 nM compared to 6.0 nM for clozapine.

IT INDEXING IN PROGRESS
IT **271-63-6**, 7-Azaindole **272-49-1**, 1H-Pyrrolo[3,2-b]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of aminoalkyl sulfonylazaindoles as 5-HT-6 ligands for treatment of mental disorder)
RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 272-49-1 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 2 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:874972 CAPLUS
DN 139:364960
TI Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
IN Wang, Tao; Zhang, Zhongxing; Meanwell, Nicholas A.; Kadow, John F.; Yin, Zhiwei; Xue, Qiufen May
PA USA
SO U.S. Pat. Appl. Publ., 277 pp., Cont.-in-part of U.S. Ser. No. 38,306.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003207910	A1	20031106	US 2002-214982	20020807
	US 2003069266	A1	20030410	US 2002-38306	20020102
PRAI	US 2001-266183P	P	20010202		
	US 2001-314406P	P	20010823		
	US 2002-38306	A2	20020102		

OS MARPAT 139:364960
GI



I



II

AB Title compds. I [n = 1 or 2; Q = (un)substituted azaindole heterocycle; A = alkoxy, (un)substituted aryl or heteroaryl; R1-8 are independently selected from H, alkyl or haloalkyl consisting of up to three halogen substituents with same or different halogens] having drug and bio-affecting properties, their pharmaceutical compns., method of use, and synthetic prepn. are disclosed. Thus, e.g., II was prepd. via palladium catalyzed coupling of 1-benzoyl-3-(R)-methyl-4-[(7-(4-fluorophenyl)-6-azaindol-3-yl)oxoacetyl]-piperazine (prepn. given) with 4-fluorophenylboronic acid. II demonstrated 56% inhibition of luciferase expression at 10 .mu.M. These compds. possess unique antiviral activity, whether used alone or in combination with other antivirals,

antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS.

IT **165669-35-2P 357263-41-3P 357263-43-5P**
357263-48-0P 357263-69-5P 425380-38-7P
446284-20-4P 446284-32-8P 446284-38-4P
446284-42-0P 446284-44-2P 446284-46-4P
446284-48-6P 446284-50-0P 446284-52-2P
446284-54-4P 446284-56-6P 446284-58-8P
446284-62-4P 619331-35-0P 619331-72-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. and antiviral activity of substituted azaindoleoxoacetic piperazine derivs.)

RN 165669-35-2 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-bromo- (9CI) (CA INDEX NAME)



RN 357263-41-3 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-chloro- (9CI) (CA INDEX NAME)



RN 357263-43-5 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine, 5-chloro-7-methyl- (9CI) (CA INDEX NAME)



RN 357263-48-0 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine, 7-chloro- (9CI) (CA INDEX NAME)



RN 357263-69-5 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-chloro-4-fluoro- (9CI) (CA INDEX NAME)



RN 425380-38-7 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 4-bromo-7-chloro- (9CI) (CA INDEX NAME)



RN 446284-20-4 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine, 7-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 446284-32-8 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-chloro-4-methoxy- (9CI) (CA INDEX NAME)



RN 446284-38-4 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-bromo-4-fluoro- (9CI) (CA INDEX NAME)



RN 446284-42-0 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 4-bromo-7-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 446284-44-2 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-bromo-4-chloro- (9CI) (CA INDEX NAME)



RN 446284-46-4 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine-7-carboxaldehyde, 4-fluoro- (9CI) (CA INDEX

NAME)



RN 446284-48-6 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 4-fluoro-7-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 446284-50-0 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine-7-carbonitrile, 4-fluoro- (9CI) (CA INDEX NAME)



RN 446284-52-2 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine-7-carboximidamide, 4-fluoro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 446284-54-4 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 4-fluoro-7-(1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)



RN 446284-56-6 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine-7-carboxylic acid, 4-fluoro- (9CI) (CA INDEX NAME)



RN 446284-58-8 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine-7-carboxamide, 4-fluoro-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 446284-62-4 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 4-fluoro-7-(1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)



RN 619331-35-0 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-bromo-4-methoxy- (9CI) (CA INDEX NAME)



RN 619331-72-5 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine-7-carbonitrile, 4-methoxy- (9CI) (CA INDEX NAME)



IT **271-29-4**, 6-Azaindole **619331-71-4**
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; prepn. and antiviral activity of substituted azaindoleoxoacetic piperazine derivs.)
RN 271-29-4 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 619331-71-4 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 4,7-dibromo- (9CI) (CA INDEX NAME)



IT **619330-60-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. and antiviral activity of substituted azaindoleoxoacetic piperazine derivs.)
RN 619330-60-8 CAPLUS
CN Piperazine, 4-benzoyl-1-[[7-(1H-indol-5-yl)-4-methoxy-1H-pyrrolo[2,3-c]pyridin-3-yl]oxoacetyl]-2-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L27 ANSWER 3 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:855655 CAPLUS
DN 139:350636
TI Preparation of amino heteroaryl amides for use in pharmaceutical compositions for the treatment of angiogenesis mediated diseases such as cancer
IN Patel, Vinod F.; Askew, Benny; Booker, Shon; Chen, Guoqing; Dipietro, Lucian V.; Germain, Julie; Habgood, Gregory J.; Huang, Qi; Kim, Tae-seong; Li, Aiwen; Nishimura, Nobuko; Nomak, Rana; Riahi, Babak; Yuan, Chester Chenguang; Elbaum, Daniel
PA Amgen Inc., USA
SO U.S. Pat. Appl. Publ., 148 pp., Cont.-in-part of U.S. Ser. No. 46,622.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003203922	A1	20031030	US 2002-197918	20020717
	US 2003195230	A1	20031016	US 2002-46622	20020110
PRAI	US 2001-261882P	P	20010112		
	US 2001-323808P	P	20010919		
	US 2002-46622	A2	20020110		

OS MARPAT 139:350636
GI



I



II

AB Amino substituted heteroaryl amides, such as I [R = nitrogen contg. heteroaryl, such as quinolinyl, isoquinolinyl, indazolyl; R1 = aryl, cycloalkyl, heteroaryl, heterocyclyl], were prepd. for therapeutic use. The invention encompasses novel compds., analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compns. and methods for prophylaxis and treatment of cancer, angiogenesis related disorders, KDR-related disorders, cell proliferation related disorders, inflammation, reducing blood flow in tumors, reducing tumor size and diabetic retinopathy. Thus, amide II was prepd. via an amination reaction of 2-chloronicotinic acid with 6-aminoquinoline followed by an amidation reaction of the aminonicotinic acid deriv. thus formed with 4-chloroaniline. Biol. evaluations included HUVEC proliferation assay, inhibition of angiogenesis in the rat corneal neovascularization micropocket model, and antitumor activity using A431 rat tumor cells.
IT **271-63-6**, 1H-Pyrrolo[2,3-b]pyridine

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of aminopyridinecarboxamides for therapeutic use in treatment of angiogenesis mediated diseases such as cancer)

RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



IT **55052-24-9P**, 1H-Pyrrolo[2,3-b]pyridine 7-oxide **55052-28-3P**
, 4-Chloro-1H-pyrrolo[2,3-b]pyridine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of aminopyridinecarboxamides for therapeutic use in treatment of angiogenesis mediated diseases such as cancer)

RN 55052-24-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 7-oxide (9CI) (CA INDEX NAME)



RN 55052-28-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-chloro- (9CI) (CA INDEX NAME)



L27 ANSWER 4 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:796705 CAPLUS
DN 139:307750
TI Preparation of 7-azaindoles as inhibitors of c-Jun N-terminal kinases
IN Graczyk, Piotr; Numata, Hirotoshi; Bhatia, Gurpreet; Medland, Darren Peter
PA Eisai London Research Laboratories Limited, UK
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003082869	A1	20031009	WO 2003-GB1115	20030317
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	GB 2002-7488	A	20020328		
	GB 2003-400	A	20030108		

OS MARPAT 139:307750
GI



I



II

AB The title compds. I [where R = (un)substituted cyclohydrocarbyl or heterocyclyl] and pharmaceutically acceptable salts, esters, amides, carbamates, carbonates, ureides, solvates, hydrates, affinity reagents, or prodrugs thereof are prepd. as inhibitors of c-Jun N-terminal kinases (JNK). I are useful for the treatment of neurodegenerative disorders related to apoptosis and/or inflammation (no data). For example, 7-aza-5-(2-thienyl)indole (II) was prepd. in a multi-step synthesis. II showed IC50 of <0.5 .mu.M against JNK3.

IT **344454-28-0P 611204-92-3P 611204-93-4P**
611204-94-5P 611204-95-6P 611204-96-7P
611204-97-8P 611204-98-9P 611204-99-0P
611205-00-6P 611205-01-7P 611205-02-8P
611205-03-9P 611205-04-0P 611205-05-1P
611205-06-2P 611205-07-3P 611205-08-4P
611205-09-5P 611205-10-8P 611205-11-9P
611205-12-0P 611205-13-1P 611205-14-2P
611205-15-3P 611205-16-4P 611205-17-5P
611205-18-6P 611205-19-7P 611205-20-0P

611205-21-1P 611205-22-2P 611205-23-3P
611205-24-4P 611205-25-5P 611205-26-6P
611205-27-7P 611205-28-8P 611205-29-9P
611205-30-2P 611205-31-3P 611205-32-4P
611205-33-5P 611205-34-6P 611205-35-7P
611205-36-8P 611205-37-9P 611205-38-0P
611205-39-1P 611205-40-4P 611205-41-5P
611205-42-6P 611205-43-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of azaindoles as inhibitors of c-jun N-terminal kinases)

RN 344454-28-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 611204-92-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 611204-93-4 CAPLUS
CN Benzenamine, N,N-dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)- (9CI) (CA INDEX NAME)



RN 611204-94-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 611204-95-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 611204-96-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 611204-97-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 611204-98-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 611204-99-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(4-ethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 611205-00-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(2,5-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 611205-01-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 611205-02-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 611205-03-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 611205-04-0 CAPLUS
CN Benzenamine, 3-(1H-pyrrolo[2,3-b]pyridin-5-yl)- (9CI) (CA INDEX NAME)



RN 611205-05-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(2-ethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 611205-06-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(3-ethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 611205-07-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 611205-08-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 611205-09-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(2,3-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 611205-10-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 611205-11-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 611205-12-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(2-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 611205-13-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(5-chloro-2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 611205-14-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(2,5-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 611205-15-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(5-methyl-2-thienyl)- (9CI) (CA INDEX NAME)



RN 611205-16-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(5-chloro-2-thienyl)- (9CI) (CA INDEX NAME)



RN 611205-17-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(2-furanyl)- (9CI) (CA INDEX NAME)



RN 611205-18-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(3,5-dimethyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 611205-19-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(1H-indol-5-yl)- (9CI) (CA INDEX NAME)



RN 611205-20-0 CAPLUS
CN Benzenamine, 2-(2-furanyl)-N,N-dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)- (9CI) (CA INDEX NAME)



RN 611205-21-1 CAPLUS
CN Benzenamine, 2-(3,5-dimethyl-4-isoxazolyl)-N,N-dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)- (9CI) (CA INDEX NAME)



RN 611205-22-2 CAPLUS
CN Benzenamine, 2-(3-furanyl)-N,N-dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)- (9CI) (CA INDEX NAME)



RN 611205-23-3 CAPLUS
CN Benzenamine, N,N-dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)-2-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 611205-24-4 CAPLUS
CN Benzenamine, 2-ethenyl-N,N-dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)- (9CI) (CA INDEX NAME)



RN 611205-25-5 CAPLUS
CN Ethanone, 1-[2-(dimethylamino)-5-(1H-pyrrolo[2,3-b]pyridin-5-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 611205-26-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(1H-indol-3-yl)- (9CI) (CA INDEX NAME)



RN 611205-27-7 CAPLUS
CN 1H-Indole, 1-(phenylsulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yl)- (9CI) (CA INDEX NAME)



RN 611205-28-8 CAPLUS
CN Benzonitrile, 2-(dimethylamino)-5-(1H-pyrrolo[2,3-b]pyridin-5-yl)- (9CI) (CA INDEX NAME)



RN 611205-29-9 CAPLUS
CN 1H-Indole, 1-(phenylsulfonyl)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)- (9CI) (CA INDEX NAME)



RN 611205-30-2 CAPLUS
CN Benzenamine, N,N-dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)-2-(2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 611205-31-3 CAPLUS
CN Benzenamine, N,N-dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)-2-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 611205-32-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(1,3-benzodioxol-5-yl)- (9CI) (CA INDEX NAME)



RN 611205-33-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(3-chloro-4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 611205-34-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(3,4-dimethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 611205-35-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(3-benzofuranyl)- (9CI) (CA INDEX NAME)



RN 611205-36-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-benzo[b]thien-3-yl- (9CI) (CA INDEX NAME)



RN 611205-37-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-[2-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 611205-38-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-phenyl- (9CI) (CA INDEX NAME)



RN 611205-39-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-[4-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 611205-40-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(5-fluoro-2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 611205-41-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(4-ethylphenyl)- (9CI) (CA INDEX NAME)



RN 611205-42-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-[4-(1,1-dimethylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 611205-43-7 CAPLUS
CN Benzenamine, N-methyl-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)- (9CI) (CA INDEX NAME)



IT **271-63-6**, 7-Azaindole
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of azaindoles as inhibitors of c-jun N-terminal kinases)
RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 5 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:796704 CAPLUS
DN 139:307749
TI Preparation of 7-azaindoles as inhibitors of c-Jun N-terminal kinases for treatment of neurodegenerative disorders
IN Graczyk, Piotr; Numata, Hirotoshi; Khan, Afzal; Palmer, Vanessa
PA Eisai London Research Laboratories Limited, UK
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003082868	A1	20031009	WO 2003-GB1112	20030317
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	GB 2002-7491	A	20020328		
	GB 2002-17330	A	20020725		

OS MARPAT 139:307749
GI



I



II

AB The title compds. I [wherein R = (un)substituted cyclohydrocarbyl or heterocyclyl; R' = (un)substituted alkyl, alkenyl, alkynyl, cyclohydrocarbyl, or heterocyclyl; R'' = H, (un)substituted alkyl, cyclohydrocarbyl, or heterocyclyl; X = O, S, (un)substituted NH, or alkylene; Y = a single bond, O, (un)substituted NH, or alkylene; Z = O, S, or (un)substituted NH] and pharmaceutically acceptable salts, esters, amides, carbamates, carbonates, ureides, solvates, hydrates, affinity reagents, or prodrugs thereof are prepd. as inhibitors of c-Jun N-terminal kinases (JNK), and are useful for the treatment of neurodegenerative disorders related to apoptosis and/or inflammation (no data). For example, the compd. II was prepd. in a multi-step synthesis. II showed IC50 of 0.52 .mu.M against JNK3 kinase.

IT **344454-28-0P 611204-93-4P 611204-95-6P**
611204-96-7P 611204-97-8P 611204-98-9P
611204-99-0P 611205-00-6P 611205-01-7P

611205-02-8P 611205-03-9P 611205-04-0P
611205-05-1P 611205-06-2P 611205-07-3P
611205-08-4P 611205-09-5P 611205-10-8P
611205-11-9P 611205-12-0P 611205-13-1P
611205-14-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of azaindoles as inhibitors of c-jun N-terminal kinases for treatment of neurodegenerative disorders)

RN 344454-28-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 611204-93-4 CAPLUS
CN Benzenamine, N,N-dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-5-yl)- (9CI) (CA INDEX NAME)



RN 611204-95-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(3,5-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 611204-96-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(1-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 611204-97-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 611204-98-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 611204-99-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(4-ethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 611205-00-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(2,5-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 611205-01-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 611205-02-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 611205-03-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 611205-04-0 CAPLUS
CN Benzenamine, 3-(1H-pyrrolo[2,3-b]pyridin-5-yl)- (9CI) (CA INDEX NAME)



RN 611205-05-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(2-ethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 611205-06-2 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 5-(3-ethoxyphenyl)- (9CI) (CA INDEX NAME)



RN 611205-07-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(2,5-dichlorophenyl)- (9CI) (CA INDEX NAME)



RN 611205-08-4 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)



RN 611205-09-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(2,3-dimethylphenyl)- (9CI) (CA INDEX NAME)



RN 611205-10-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 611205-11-9 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 611205-12-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(2-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 611205-13-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(5-chloro-2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 611205-14-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-(2,5-dimethylphenyl)- (9CI) (CA INDEX NAME)



IT **611204-92-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of azaindoles as inhibitors of c-jun N-terminal kinases for treatment of neurodegenerative disorders)
RN 611204-92-3 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 5-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



IT **271-63-6**, 7-Azaindole
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of azaindoles as inhibitors of c-jun N-terminal kinases for treatment of neurodegenerative disorders)
RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 6 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:796491 CAPLUS
DN 139:307795
TI Process for the preparation of antiviral 7-azaindole derivatives
IN Benoit, Serge; Gingras, Stephane; Soundararajan, Nachimuthu
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003082289	A1	20031009	WO 2003-US9055	20030325

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-367401P P 20020325
OS MARPAT 139:307795
GI



I



II

AB A process for the manuf. of azaindoles I [R1, R3, R4 = H, alkyl, alkenyl, cycloalkenyl, alkynyl, halogen, CN, Ph, acyl, (un)substituted CONH2, OH,

SH, NH2; R2 = Me, Et, CH2CF3, Pr; R5 = H, alkyl, cycloalkyl, cyclolakenyl, CH2Ph, alkenyl, alkynyl, (un)substituted CONH2; Ar = (un)substituted Ph, pyridyl, furyl, thienyl; the piperazine ring may be further substituted] is described. The products are useful as therapeutic agents for the treatment of HIV and AIDS. Thus, 1H-pyrrolo[2,3-b]pyridine was oxidized with 3-ClC6H4CO2OH to its 7-oxide which was chlorinated with MeSO2Cl in MeCN to give 4-chloro-1H-pyrrolo[2,3-b]pyridine. This compd. was converted to the 4-methoxy deriv. by treatment with KOMe in PhMe and treated with ClCOCO2Me in presence of AlCl3 to give Me (4-methoxy-7-azaindol-3-yl)oxoacetate which was hydrolyzed to the acid and amidated with vilsmeier reagent and (R)-3-methyl-1-benzoylpiperazine to give the azaindole II.

IT **55052-24-9P 55052-28-3P 122379-63-9P 611197-49-0P**
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(process for the prepn. of antiviral 7-azaindole derivs.)

RN 55052-24-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 7-oxide (9CI) (CA INDEX NAME)



RN 55052-28-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-chloro- (9CI) (CA INDEX NAME)



RN 122379-63-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-methoxy- (9CI) (CA INDEX NAME)



RN 611197-49-0 CAPLUS
CN Benzoic acid, 3-chloro-, compd. with 1H-pyrrolo[2,3-b]pyridine 7-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 55052-24-9
CMF C7 H6 N2 O



CM 2

CRN 535-80-8
CMF C7 H5 Cl O2



IT **271-63-6,** 1H-Pyrrolo[2,3-b]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(process for the prepn. of antiviral 7-azaindole derivs.)
RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 7 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:678772 CAPLUS
DN 139:214465
TI Preparation of substituted phenylalkanoic acid derivatives as inhibitors of prostaglandin and leukotriene production
IN Shoda, Motoshi; Kuriyama, Hiroshi
PA Asahi Kasei Kabushiki Kaisha, Japan
SO PCT Int. Appl., 607 pp.
CODEN: PIXXD2
DT **Patent**
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003070686	A1	20030828	WO 2003-JP1849	20030220

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI JP 2002-45293 A 20020221
JP 2002-301543 A 20021016
OS MARPAT 139:214465
GI



I

AB Compds. represented by the general formula (I) [wherein n is an integer of 1 to 3; R represents C3-8 alkyl, a group represented by R1(CH2)k- (k is an integer of 0 to 3; and R1 represents C3-7 satd. cycloalkyl or C6-8 fused-ring satd. alkyl, provided that R1 may be substituted by C1-4 alkyl), etc.; and Ar represents a bicyclic fused-ring group, e.g., naphthalen-1-yl, indolyl, benzothiazolyl, quinolyl, isoquinolyl, indazolyl] or salts thereof are prepd. The compds. I or salt thereof have prostaglandin and leukotriene prodn. inhibitory activity and are useful for the prevention of and treatments for various acute or chronic inflammatory diseases attributable to the lipid mediator, allergic diseases, and autoimmune diseases, and for antipyresis and/or analgesia. Thus, 3-(3-bromo-5-fluoro-4-cyclopentyloxyphenyl)propionic acid Me ester (prepn. given) was coupled with 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2-methylaniline in the presence of (Ph3P)4Pd in 2 M aq. Na2CO3 soln. and toluene at 100.degree. for 15 h to give 3-(4'-amino-6-cyclopentyloxy-5-fluoro-3'-methyl-1,1'-biphenyl-3-yl)propionic acid Me ester which was

dissolved in AcOH under ice cooling, treated with aq. NaNO2 soln., stirred for 30 min, treated with urea, warmed to room temp., and stirred for 30 min to give 3-[4-cyclopentyloxy-3-fluoro-5-(1H-indazol-5-yl)phenyl]propionic acid Me ester (II). Sapon. of II by 2 N aq. NaOH in MeOH at 60.degree. for 16 h followed by concn. under reduced pressure and acidification with 5% aq. HCl under ice-cooling gave 3-[4-cyclopentyloxy-3-fluoro-5-(1H-indazol-5-yl)phenyl]propionic acid (III). III, 3-[4-(cyclohexylmethoxy)-3-(6-hydroxynaphthalen-2-yl)phenyl]propionic acid, and 3-[4-(cyclopentylmethoxy)-3-(1H-indol-5-yl)phenyl]propionic acid inhibited the interleukin-1.beta.-stimulated prostaglandin E2 in human osteosarcoma cell (MG-63) by .gtoreq.50% at 0.4 .mu.M.

IT **590416-03-8P 590416-04-9P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted phenylalkanoic acid derivs. as inhibitors of prostaglandin and leukotriene prodn. for prevention or treatment of inflammations, allergies, and autoimmune diseases, and for antipyresis and/or analgesia)

RN 590416-03-8 CAPLUS
CN Benzenepropanoic acid, 4-(cyclopentyloxy)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 590416-04-9 CAPLUS
CN Benzenepropanoic acid, 4-(cyclopentyloxy)-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)- (9CI) (CA INDEX NAME)



IT **271-63-6**, 1H-Pyrrolo[2,3-b]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of substituted phenylalkanoic acid derivs. as inhibitors of prostaglandin and leukotriene prodn. for prevention or treatment of inflammations, allergies, and autoimmune diseases, and for antipyresis and/or analgesia)

RN 271-63-6 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



IT **183208-35-7P**, 5-Bromo-1H-pyrrolo[2,3-b]pyridine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of substituted phenylalkanoic acid derivs. as inhibitors of prostaglandin and leukotriene prodn. for prevention or treatment of inflammations, allergies, and autoimmune diseases, and for antipyresis and/or analgesia)
RN 183208-35-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 8 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:610442 CAPLUS
DN 139:164806
TI Preparation of quinazolines as VEGF receptor inhibitors
IN Hennequin, Laurent Francois Andre
PA Astrazeneca R & D Sodertalje, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 195 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003064413	A1	20030807	WO 2003-GB343	20030128

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI EP 2002-290242 A 20020201
OS CASREACT 139:164806; MARPAT 139:164806
GI



I



II

AB The title compds. [I; ring C = indolyl, indazolyl or azaindolyl; Z = O,

NH, S; n = 0-5; m = 0-3; R2 = H, OH, halo, etc.; R1 = H, halo, oxo, OH, etc.], useful in the manuf. of a medicament for use in the prodn. of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals, were prepd. and formulated. E.g., a multi-step synthesis of II, was given. The compds. I inhibit the effects of VEGF, a property of value in the treatment of a no. of disease states including cancer and rheumatoid arthritis (no biol. data).

IT **574745-15-6P 574745-16-7P 574745-17-8P**
574745-18-9P 574745-19-0P 574745-38-3P
574745-47-4P 574745-54-3P 574745-57-6P
574745-60-1P 574745-62-3P 574745-63-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of quinazolines as VEGF inhibitors)

RN 574745-15-6 CAPLUS
CN Piperazine, 1-[3-[[7-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-6-quinazolinyl]oxy]propyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 574745-16-7 CAPLUS
CN Piperazine, 1-acetyl-4-[3-[[7-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-6-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 574745-17-8 CAPLUS
CN Piperazine, 1-acetyl-4-[3-[[6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 574745-18-9 CAPLUS
CN Piperazine, 1-[3-[[7-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]propyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 574745-19-0 CAPLUS
CN 2-Propyn-1-amine, N-[2-[[6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 574745-38-3 CAPLUS
CN Quinazoline, 6-methoxy-7-[3-[4-(2-propenyl)-1-piperazinyl]propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (9CI) (CA INDEX NAME)



RN 574745-47-4 CAPLUS
CN 1-Piperazinecarboxamide, 4-[3-[[6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 574745-54-3 CAPLUS
CN Piperazine, 1-acetyl-4-[2-[[6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]ethyl]- (9CI) (CA INDEX NAME)



RN 574745-57-6 CAPLUS
CN 1-Piperazineacetamide, 4-[3-[[6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]propyl]- (9CI) (CA INDEX NAME)



RN 574745-60-1 CAPLUS
CN 1,3-Dioxolo[4,5-g]quinazoline, 8-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (9CI) (CA INDEX NAME)



RN 574745-62-3 CAPLUS
CN Quinazoline, 7-[2-[4-(2-fluoroethyl)-1-piperazinyl]ethoxy]-6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (9CI) (CA INDEX NAME)



RN 574745-63-4 CAPLUS
CN Quinazoline, 6-methoxy-7-[3-[4-(2-propynyl)-1-piperazinyl]propoxy]-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (9CI) (CA INDEX NAME)



IT **271-63-6**, 7-Azaindole
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of quinazolines as VEGF inhibitors)
RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



IT **98549-88-3P**, 1H-Pyrrolo[2,3-b]pyridin-5-ol **183208-35-7P**,
5-Bromo-7-azaindole **183208-36-8P 574745-69-0P**
574745-70-3P 574745-99-6P 574746-00-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of quinazolines as VEGF inhibitors)
RN 98549-88-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-5-ol (6CI, 9CI) (CA INDEX NAME)



RN 183208-35-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo- (9CI) (CA INDEX NAME)



RN 183208-36-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-methoxy- (9CI) (CA INDEX NAME)



RN 574745-69-0 CAPLUS
CN Quinazoline, 7-methoxy-6-(phenylmethoxy)-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (9CI) (CA INDEX NAME)



RN 574745-70-3 CAPLUS
CN 6-Quinazolinol, 7-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)- (9CI) (CA INDEX NAME)



RN 574745-99-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[3-[[6-methoxy-4-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-7-quinazolinyl]oxy]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 574746-00-2 CAPLUS
CN Quinazoline, 6-methoxy-7-[3-(1-piperazinyl)propoxy]-4-(1H-pyrrolo[2,3-

b]pyridin-5-yloxy)- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 9 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:511332 CAPLUS
DN 139:85327
TI Preparation of azaindolylalkylamines as 5-hydroxytryptamine-6 ligands
IN Bernotas, Ronald Charles; Cole, Derek Cecil; Lennox, William Joseph
PA Wyeth, John, and Brother Ltd., USA
SO PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003053970	A1	20030703	WO 2002-US40220	20021217
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003171395	A1	20030911	US 2002-323263	20021219
PRAI	US 2001-342838P	P	20011220		

OS MARPAT 139:85327
GI



I

AB The title compds. [I; W = SO2, CO, CONR11, CSNR12; X = N, CR1; Y = N, CR2; Z = N, CR3; Q = N, CR4, with the proviso that no more than two of X, Y, Z and Q may be N; n = 2-3; R1-R4 = H, halo, CN, etc.; R5, R6 = H, alkyl, cycloalkyl, etc.; R7, R8 = H, (un)substituted alkyl; R9 = H, halo, alkyl, etc.; R10 = (un)substituted alkyl, aryl, heteroaryl, etc.; R11, R12 = H, (un)substituted alkyl, aryl, heteroaryl], useful for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor, were prepd. E.g., a multi-step synthesis of I [X = N; Y, Z, Q = CH; W = SO2; R5-R9 = H; R10 = 2-ClC6H4; n = 2], starting with 2-chloro-3-nitropyridine and tert-Bu cyanoacetate, which showed Ki of 5.0 nM against 5-HT6 binding, was given.

IT **271-63-6**, 7-Azaindole
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of azaindolylalkylamines as 5-hydroxytryptamine-6 ligands)

RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



IT **271-34-1P**, 5-Azaindole **272-49-1P**, 4-Azaindole
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of azaindolylalkylamines as 5-hydroxytryptamine-6 ligands)
RN 271-34-1 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 272-49-1 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 10 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:417745 CAPLUS
DN 139:6867
TI Preparation of heteroarylalkanoic acids as aldose reductase inhibitors for treatment of diabetic complications.
IN Van Zandt, Michael C.; Geraci, Leo
PA The Institute for Pharmaceutical Discovery, LLC, USA
SO PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003044015	A2	20030530	WO 2002-US36709	20021115
	WO 2003044015	A3	20031002		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003166668	A1	20030904	US 2002-295414	20021114
PRAI	US 2001-336055P	P	20011115		
	US 2002-378626P	P	20020507		

OS MARPAT 139:6867
GI



AB DACOR' [D = Q1, Q2, Q3, etc.; Y = ZAr; Z = bond, O, S, CONH, alkylene optionally substituted with Me, Et; Ar = (substituted) aryl, aralkyl; R3 = H, halo, OH , alkyl, haloalkyl, amino, alkylamino, dialkylamino, aryl, SR15, OR15; R15 = alkyl, aryl, arylalkyl; R' = OH, PhCH2O, dialkylaminoethoxy, acetoxymethyl, pivaloyloxymethyl, etc.], were prepd.

Thus, Et [3-cyanomethyl-6-ethylpyrrolo[2,3-b]pyridin-1-yl]acetate (prepn. given), 2-amino-3,4,6-trifluorothiophenol hydrochloride (prepn. given) and BHT were heated in a sealed reaction vessel at 120.degree. for 9 h to give 86% Et [6-ethyl-3-(4,5,7-trifluorobenzothiazol-2-ylmethyl)pyrrolo[2,3-b]pyridin-1-yl]acetate. The latter and BHT in 1,2-dimethoxyethane were cooled to 0.degree. and treated with 1 N NaOH followed by stirring 30 min, acidification to pH 3-4 with 1 N HCl and extn. with Et acetate to give 56% [6-ethyl-3-(4,5,7-trifluorobenzothiazol-2-ylmethyl)pyrrolo[2,3-b]pyridin-1-yl]acetic acid. The latter inhibited human aldose reductase with IC50 = 12 nM.

IT **271-63-6**, 7-Azaindole
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of heteroarylalkanoic acids as aldose reductase inhibitors for treatment of diabetic complications)

RN 271-63-6 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



IT **533939-04-7P**, 6-Ethyl-1H-pyrrolo[2,3-b]pyridine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of heteroarylalkanoic acids as aldose reductase inhibitors for treatment of diabetic complications)

RN 533939-04-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 6-ethyl- (9CI) (CA INDEX NAME)



L27 ANSWER 11 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:5959 CAPLUS
DN 138:73275
TI Synthesis of heterocyclic compounds employing microwave technology
IN Majid, Tahir Nadeem; Deprets, Stephanie D.; Pedgrift, Brian L.
PA Aventis Pharmaceuticals Inc., USA
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003000690	A1	20030103	WO 2002-US20206	20020625

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-300733P P 20010625
GB 2001-19307 A 20010808
OS CASREACT 138:73275; MARPAT 138:73275
GI



I



II

AB The heterocycles I (X = N, CR4, Y and Z = CH, CHR3, W = N; X = CR4, Y and W = N, Z = CR3; Y = CR3, Z and W = N, X = N, CR4; Y = bond, W = N, Z = CR5, X = O, S, NR6; Y = bond, W = N, X = CR4, Z = O, S, NR7; Y = bond, W = O, X = CR4, Z = N, CR5; Y = bond, W = O, X = N, Z = CR5; R1 = aryl, heteroaryl which may be optionally substituted; R2 = H, acyl, cyano, halo, alkenyl, etc.; R3 = H, aryl cyano, halo, heteroaryl, etc.; R4 = H, halo, cyano, OH, nitro, etc.; R5 = cyano, H, amino, etc., R6 = H, cyano,, alkyl, cycloalkyl, CO2H, carbamoyl, etc.; R7 = H, alkyl) were prepd. using microwave energy. Thus, a microwave tube was charged with 6-(4-trifluoromethylsulfonyloxyphenyl)-5H-pyrrolo[2,3-b]pyrazine, pyrrolidine and dioxane and DMF, and heated at 200.degree. in an microwave oven for 1 h to give 6-(4-pyrrolidinophenyl)-5H-pyrrolo[2,3-b]pyrazine (II).

IT **271-63-6**, 1H-Pyrrolo[2,3-b]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of heterocyclic compds. employing microwave technol.)

RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



IT **55052-24-9P 55052-28-3P 348640-06-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of heterocyclic compds. employing microwave technol.)
RN 55052-24-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 7-oxide (9CI) (CA INDEX NAME)



RN 55052-28-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-chloro- (9CI) (CA INDEX NAME)



RN 348640-06-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-bromo- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 12 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:5957 CAPLUS
DN 138:55984
TI Preparation of azaindoles as protein kinase inhibitors
IN Cox, Paul Joseph; Majid, Tahir Nadeem; Lai, Justine Yeun Quai; Morley, Andrew; Amendola, Shelley; Deprets, Stephanie Daniele; Edlin, Chris; Gardner, Charles J.; Kominos, Dorothea; Pedgrift, Brian Leslie; Halley, Frank; Gillespy, Timothy Alan; Edwards, Michael; Clerc, Francois Frederic; Nemecek, Conception; Houille, Olivier; Damour, Dominique; Bouchard, Herve; Bezard, Daniel; Carrez, Chantal
PA Aventis Pharma Limited, UK
SO PCT Int. Appl., 373 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003000688	A1	20030103	WO 2002-GB2799	20020620
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	GB 2001-15109	A	20010621		
	US 2001-300257P	P	20010622		

OS MARPAT 138:55984
GI



I

AB The invention is directed to physiol. active azaindoles (shown as I; variables defined below; e.g. 6-(5-methoxy-1-methyl-1H-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine) and compns. contg. such compds.; and their prodrugs, and pharmaceutically acceptable salts and solvates of such compds. and their prodrugs. Such compds. and compns. have valuable pharmaceutical properties, in particular the ability to inhibit kinases, esp. Syk, FAK, KDR, Aurora2 and IGF1R (data given in general rather than for specific I). Although the methods of prepn. are not claimed, >100 example prepns. of intermediates and I are included. For I: R1 = aryl or heteroaryl each optionally substituted by .gtoreq.1 groups = alkylenedioxy, alkenyl, alkenyloxy, alkynyl, aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, R4, -C(O)R, -C(O)OR5, -C(O)NY1Y2, -NY1Y2, -N(R6)C(O)R7, -N(R6)C(O)NY3Y4, -N(R6)C(O)OR7, -N(R6)SO2R7, -N(R6)SO2NY3Y4, -SO2NY1Y2 and -Z2R. R2 = H, acyl, cyano, halo, lower

alkenyl, -Z2R4, -SO2NY3Y4, -NY1Y2 or lower alkyl optionally substituted by aryl, cyano, heteroaryl, heterocycloalkyl, hydroxy, -Z2R4, -C(O)NY1Y2, -C(O)R, -CO2R8, -NY3Y4, -N(R6)C(O)R, -N(R6)C(O)NY1Y2, -N(R6)C(O)OR7, -N(R6)SO2R7, -N(R6)SO2NY3Y4, -SO2NY1Y2 and .gtoreq.1 halogen atoms. R3 = H, aryl, cyano, halo, heteroaryl, lower alkyl, -Z2R4, -C(O)OR5 or -C(O)NY3Y4. R4 = alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl each optionally substituted by aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, -CHO (or a 5- 6- or 7-membered cyclic acetal deriv. thereof), -C(O)NY1Y2, -C(O)OR5, -NY1Y2, -N(R6)C(O)R7, -N(R6)C(O)NY3Y4, -N(R6)SO2R7, -N(R6)SO2NY3Y4, -Z3R7 and .gtoreq.1 hydroxy, alkoxy and carboxy. R5 = H, alkyl, alkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl. R6 = H or lower alkyl; R7 = alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; R8 = H or lower alkyl. R = aryl or heteroaryl; alkenyl; or alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl each optionally substituted by aryl, cycloalkyl, cyano, halo, heteroaryl, heterocycloalkyl, -CHO (or a 5- 6- or 7-membered cyclic acetal deriv. thereof), -C(O)NY1Y2, -C(O)OR5, -NY1Y2, -N(R6)C(O)R7, -N(R6)C(O)NY3Y4, -N(R6)SO2R7, -N(R6)SO2NY3Y4, -Z3R7 and .gtoreq.1 hydroxy, alkoxy and carboxy. X1 = N, CH, C-aryl, C-heteroaryl, C-heterocycloalkyl, C-heterocycloalkenyl, C-halo, C-CN, C-R4, CNY1Y2, COH, CZ2R, CC(O)R, CC(O)OR5, CC(O)NY1Y2, CN(R8)C(O)R, CN(R6)C(O)OR7, CN(R6)C(O)NY3Y4, CN(R6)SO2NY3Y4, CN(R6)SO2R, CSO2NY3Y4, C-NO2, or C-alkenyl or C-alkynyl optionally substituted by .gtoreq.1 aryl, cyano, halo, hydroxy, heteroaryl, heterocycloalkyl, nitro, -C(O)NY1Y2, -C(O)OR5, -NNY1Y2, -N(R6)C(O)R7, -N(R6)C(O)NY3Y4, -N(R6)C(O)OR7, -N(R6)SO2R7, -N(R6)SO2NY3Y4, -SO2NY1Y2 and -Z2R4. Y1 and Y2 = H, alkenyl, aryl, cycloalkyl, heteroaryl or alkyl optionally substituted by .gtoreq.1 aryl, halo, heteroaryl, heterocycloalkyl, hydroxy, -C(O)NY3Y4, -C(O)OR5, NY3Y4, -N(R6)C(O)R7, -N(R6)C(O)NY3Y4, -N(R6)SO2R7, -N(R6)SO2NY3Y4 and -OR7, or the group -NY1Y2 may form a cyclic amine. Y3 and Y4 = H, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group -NY3Y4 may form a cyclic amine; Z1 = O or S; Z2 = O or S(O)n; Z3 = O, S(O)n, NR6; n = 0-2.

IT **271-63-6**, 1H-Pyrrolo[2,3-b]pyridine **83683-82-3**, 4-Nitro-1H-pyrrolo[2,3-b]pyridine **183208-35-7**, 5-Bromo-1H-pyrrolo[2,3-b]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of azaindoles as protein kinase inhibitors with therapeutic uses)

RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 83683-82-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-nitro- (9CI) (CA INDEX NAME)



RN 183208-35-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo- (9CI) (CA INDEX NAME)



IT **55052-24-9P**, 1H-Pyrrolo[2,3-b]pyridine-N-oxide **55052-28-3P**, 4-Chloro-1H-pyrrolo[2,3-b]pyridine **74420-02-3P**, 1H-Pyrrolo[2,3-b]pyridine-4-ol **122379-63-9P**, 4-Methoxy-1H-pyrrolo[2,3-b]pyridine **348640-54-0P**, 4-Phenyl-1H-pyrrolo[2,3-b]pyridine **351439-07-1P**, 1H-Pyrrolo[2,3-b]pyridine-4-carboxylic acid methyl ester **479552-73-3P**, 1H-Pyrrolo[2,3-b]pyridine-4-carboxylic acid tert-butyl ester **479552-75-5P**, 4-(Pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridine **479552-78-8P**, 4-(3,5-Dimethylisoxazol-4-yl)-1H-pyrrolo[2,3-b]pyridine **479552-94-8P**, Trifluoromethanesulfonic acid 1H-pyrrolo[2,3-b]pyridin-4-yl ester **479553-01-0P**, 1H-Pyrrolo[2,3-b]pyridine-4-carboxylic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of azaindoles as protein kinase inhibitors with therapeutic uses)

RN 55052-24-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 7-oxide (9CI) (CA INDEX NAME)



RN 55052-28-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-chloro- (9CI) (CA INDEX NAME)



RN 74420-02-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridin-4-ol (9CI) (CA INDEX NAME)



RN 122379-63-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-methoxy- (9CI) (CA INDEX NAME)



RN 348640-54-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-phenyl- (9CI) (CA INDEX NAME)



RN 351439-07-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-4-carboxylic acid, methyl ester (9CI) (CA INDEX NAME)



RN 479552-73-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-4-carboxylic acid, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 479552-75-5 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 479552-78-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-(3,5-dimethyl-4-isoxazolyl)- (9CI) (CA INDEX NAME)



RN 479552-94-8 CAPLUS
CN Methanesulfonic acid, trifluoro-, 1H-pyrrolo[2,3-b]pyridin-4-yl ester (9CI) (CA INDEX NAME)



RN 479553-01-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-4-carboxylic acid (9CI) (CA INDEX NAME)



IT **344327-11-3P,** 1H-Pyrrolo[2,3-b]pyridine-4-carbonitrile
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of azaindoles as protein kinase inhibitors with therapeutic uses)
RN 344327-11-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-4-carbonitrile (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 13 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:658748 CAPLUS
DN 137:201296
TI Preparation of antiviral azaindole derivatives
IN Wang, Tao; Wallace, Owen B.; Zhang, Zhongxing; Meanwell, Nicholas A.; Bender, John A.
PA USA
SO U.S. Pat. Appl. Publ., 60 pp., Cont.-in-part of U.S. Ser. No. 765,189.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002119982	A1	20020829	US 2001-912710	20010725
	US 6476034	B2	20021105		
	US 2002061892	A1	20020523	US 2001-765189	20010118
	US 2003181463	A1	20030925	US 2002-268350	20021010
	US 6632819	B1	20031014		
PRAI	US 2000-184004P	P	20000222		
	US 2001-765189	A2	20010118		
	US 2001-912710	A3	20010725		

OS MARPAT 137:201296
GI



I

AB The present invention is directed to a series of chem. entities that express HIV-1 inhibitory activities. Thus, azaindoles I [R1-R4 = H, alkyl, cycloalkyl, halo, etc.; R5 = Om and m = 0, 1; n = 1, 2; R6 = H, alkyl, alkenyl, etc.; R7-R14 = H, alkyl, cycloalkyl, etc.; Ar = (un)substituted Ph, 2-pyridyl, 2-furyl, etc.] were prepd. E.g., (R)-N-benzoyl-3-methyl-N'-[(7-azaindol-3-yl)oxoacetyl]piperazine was prepd.

IT **425380-38-7P 446284-32-8P 452296-79-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of antiviral azaindole derivs.)

RN 425380-38-7 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 4-bromo-7-chloro- (9CI) (CA INDEX NAME)



RN 446284-32-8 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-chloro-4-methoxy- (9CI) (CA INDEX NAME)



RN 452296-79-6 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 4,7-dimethoxy- (9CI) (CA INDEX NAME)



IT **271-34-1**, 5-Azaindole **271-63-6**, 7-Azaindole
357263-40-2, 1H-Pyrrolo[2,3-c]pyridine, 4-methoxy-
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of antiviral azaindole derivs.)
RN 271-34-1 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 357263-40-2 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 4-methoxy- (9CI) (CA INDEX NAME)



IT **160590-40-9P**, 7-Methoxy-6-azaindole **357263-41-3P**,
1H-Pyrrolo[2,3-c]pyridine, 7-chloro- **357263-42-4P**,
1H-Pyrrolo[3,2-b]pyridine, 7-methyl- **357263-43-5P**,
1H-Pyrrolo[3,2-b]pyridine, 5-chloro-7-methyl- **357263-44-6P**,
1H-Pyrrolo[3,2-b]pyridine, 7-(phenylmethoxy)- **357263-48-0P**,
1H-Pyrrolo[3,2-b]pyridine, 7-chloro- **357263-68-4P**,
1H-Pyrrolo[2,3-c]pyridine, 5,7-dibromo-4-methoxy- **357263-69-5P**,
1H-Pyrrolo[2,3-c]pyridine, 7-chloro-4-fluoro-
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of antiviral azaindole derivs.)
RN 160590-40-9 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-methoxy- (9CI) (CA INDEX NAME)



RN 357263-41-3 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-chloro- (9CI) (CA INDEX NAME)



RN 357263-42-4 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine, 7-methyl- (9CI) (CA INDEX NAME)



RN 357263-43-5 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine, 5-chloro-7-methyl- (9CI) (CA INDEX NAME)



RN 357263-44-6 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine, 7-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 357263-48-0 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine, 7-chloro- (9CI) (CA INDEX NAME)



RN 357263-68-4 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 5,7-dibromo-4-methoxy- (9CI) (CA INDEX NAME)



RN 357263-69-5 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-chloro-4-fluoro- (9CI) (CA INDEX NAME)



L27 ANSWER 14 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:615461 CAPLUS
DN 137:169502
TI Preparation and antiviral activity for HIV-1 of substituted azaindoleoxoacetylpiperazines
IN Wang, Tao; Zhang, Zhongxing; Meanwell, Nicholas A.; Kadow, John F.; Yin, Zhiwei
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 367 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062423	A1	20020815	WO 2002-US455	20020102
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1363705	A1	20031126	EP 2002-707413	20020102
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NO 2003003436	A	20031001	NO 2003-3436	20030801
PRAI	US 2001-266183P	P	20010202		
	US 2001-314406P	P	20010823		
	WO 2002-US455	W	20020102		

OS MARPAT 137:169502
GI



I

AB Title compds. Q(CO)nWCOA [Q = (un)substituted azaindolyl; W = (un)substituted piperazino; A = (un)substituted alkoxy, aryl, heteroaryl; n = 1, 2] were prepd. for use as antiviral agents, alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors, in the treatment of HIV and AIDS. Thus, 2-chloro-3-

nitropyridine was cyclized with vinylmagnesium bromide to give 7-chloro-6-azaindole which was treated with ClCOCO2Me, followed by ester hydrolysis, amidation with (R)-3-methyl-1-benzoylpiperazine, and substitution with 4-FC6H4B(OH)2 to give the title compd. I which had an EC50 for HIV-1 in vitro of <1 .mu.M.

IT **271-29-4**, 6-Azaindole
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. and antiviral activity for HIV-1 of substituted azaindoleoxoacetylpiperazines)

RN 271-29-4 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



IT **165669-35-2P 357263-41-3P**, 7-Chloro-6-azaindole
357263-43-5P 357263-48-0P 357263-69-5P
425380-38-7P 446284-20-4P 446284-32-8P
446284-38-4P 446284-42-0P 446284-44-2P
446284-46-4P 446284-48-6P 446284-50-0P
446284-52-2P 446284-54-4P 446284-56-6P
446284-58-8P 446284-60-2P 446284-62-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and antiviral activity for HIV-1 of substituted azaindoleoxoacetylpiperazines)

RN 165669-35-2 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-bromo- (9CI) (CA INDEX NAME)



RN 357263-41-3 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-chloro- (9CI) (CA INDEX NAME)



RN 357263-43-5 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine, 5-chloro-7-methyl- (9CI) (CA INDEX NAME)



RN 357263-48-0 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine, 7-chloro- (9CI) (CA INDEX NAME)



RN 357263-69-5 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-chloro-4-fluoro- (9CI) (CA INDEX NAME)



RN 425380-38-7 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 4-bromo-7-chloro- (9CI) (CA INDEX NAME)



RN 446284-20-4 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine, 7-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 446284-32-8 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-chloro-4-methoxy- (9CI) (CA INDEX NAME)



RN 446284-38-4 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-bromo-4-fluoro- (9CI) (CA INDEX NAME)



RN 446284-42-0 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 4-bromo-7-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 446284-44-2 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-bromo-4-chloro- (9CI) (CA INDEX NAME)



RN 446284-46-4 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine-7-carboxaldehyde, 4-fluoro- (9CI) (CA INDEX NAME)



RN 446284-48-6 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 4-fluoro-7-(5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 446284-50-0 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine-7-carbonitrile, 4-fluoro- (9CI) (CA INDEX NAME)



RN 446284-52-2 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine-7-carboximidamide, 4-fluoro-N-hydroxy- (9CI) (CA INDEX NAME)



RN 446284-54-4 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 4-fluoro-7-(1,2,4-oxadiazol-3-yl)- (9CI) (CA INDEX NAME)



RN 446284-56-6 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine-7-carboxylic acid, 4-fluoro- (9CI) (CA INDEX NAME)



RN 446284-58-8 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine-7-carboxamide, 4-fluoro-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 446284-60-2 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine, 7-bromo-4-methoxy- (9CI) (CA INDEX NAME)



RN 446284-62-4 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 4-fluoro-7-(1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 15 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:487577 CAPLUS
DN 137:63420
TI Preparation of lactone ketolide macrolide erythromycin antibiotics
IN Andreotti, Daniele; Arista, Luca; Biondi, Stefano; Cardullo, Francesca; Damiani, Frederica; Lociuro, Sergio; Marchioro, Carla; Merlo, Giancarlo; Mingardi, Anna; Niccolai, Daniela; Paio, Alfredo; Piga, Elisabetta; Pozzan, Alfonso; Seri, Catia; Tarsi, Luca; Terreni, Silvia; Tibasco, Jessica
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 215 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050091	A1	20020627	WO 2001-GB5665	20011220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002017277	A5	20020701	AU 2002-17277	20011220
	EP 1363925	A1	20031126	EP 2001-271380	20011220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NO 2003002846	A	20030820	NO 2003-2846	20030620
PRAI	GB 2000-31309	A	20001221		
	GB 2001-26276	A	20011101		
	GB 2001-26277	A	20011101		
	WO 2001-GB5665	W	20011220		

OS MARPAT 137:63420
GI



I

AB The present invention relates to lactone ketolides I wherein R is H, CN,

substituted alkyl; R1 is alkyl, alkenyl; R2 is H, hydroxy protecting group; R3 is H, halogen, and pharmaceutically acceptable salts and solvates thereof, to process for their prepn. and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body. Thus, (11S,21R)-3-decladinosyl-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl-(cyano)-methylene]erythromycin A was prepd. and tested as antibacterial agent against Streptococcus pneumoniae and Streptococcus pyogenes (MIC .ltoreq. 1 .mu.g/mL).

IT **271-63-6**, 1H-Pyrrolo[2,3-b]pyridine **17288-40-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of lactone ketolide macrolide erythromycin antibiotics and their use in therapy or prophylaxis of systemic or topical bacterial infections)

RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 17288-40-3 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine, 5-methoxy- (8CI, 9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 16 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:428923 CAPLUS
DN 137:17028
TI Synthesis of nucleic acid aptamers having non Watson-Crick base and use for DNA sequencing
IN Hayashizaki, Yoshihide
PA Riken Corp., Japan; Kabushiki Kaisha Dynaform
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002044195	A2	20020606	WO 2001-JP10400	20011128
	WO 2002044195	A3	20030327		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002018490	A5	20020611	AU 2002-18490	20011128
	EP 1348035	A2	20031001	EP 2001-998557	20011128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2000-253097P	P	20001128		
	WO 2001-JP10400	W	20011128		

AB The present invention provides aptamers comprising at least one base capable of base pairing and different from the std. Watson-Crick bases. The present invention also relates to a method for prepn. of such aptamers and to methods for sequencing nucleic acids that comprise at least one base capable of base pairing and different from the std. Watson-Crick bases. Aptamers are nucleic acids that specifically assoc. with a ligand. The present inventor has surprisingly found that nucleic acid aptamers comprising at least one base capable of base pairing and different from the std. Watson-Crick (W-C) bases are particularly useful for the selection of new and specific ligands.

IT **271-34-1**, 1H-Pyrrolo[3,2-c]pyridine **271-63-6**, 7-Azaindole **824-51-1**
RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)
(non W-C std. base; synthesis of nucleic acid aptamers having non Watson-Crick base and use for DNA sequencing)

RN 271-34-1 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 271-63-6 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 824-51-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 6-methyl- (7CI, 8CI, 9CI) (CA INDEX NAME)



L27 ANSWER 17 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:184900 CAPLUS
DN 136:247577
TI Preparation of 3-phenyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines as cathepsin S inhibitors for treating allergies
IN Cai, Hui; Edwards, James P.; Gu, Yin; Karlsson, Lars; Meduna, Steven P.; Pio, Barbara A.; Sun, Siquan; Thurmond, Robin L.; Wei, Jianmei
PA Ortho McNeil Pharmaceutical, Inc., USA
SO PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002020013	A2	20020314	WO 2001-US27480	20010905
	WO 2002020013	A3	20020620		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002040019	A1	20020404	US 2001-927188	20010810
	US 6635633	B2	20031021		
	AU 2001088731	A5	20020322	AU 2001-88731	20010905
	EP 1315492	A2	20030604	EP 2001-968487	20010905
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2000-230407P	P	20000906		
	US 2001-927188	A	20010810		
	US 2000-225178P	P	20000814		
	WO 2001-US27480	W	20010905		

OS MARPAT 136:247577
GI



I



II

AB Title compds. I [wherein Ar = (un)substituted mono- or bicyclic (hetero)aryl; G = (un)substituted alkenediyl or alkanediyl; Q = O, S, or (un)substituted N; S, T, Y, and Z = independently N or (un)substituted C; R5 and R6 = independently H or alkyl; R7 and R8 = independently H, alkyl, alkenyl, alkoxy, alkylthio, halo, carbocyclyl, or heterocyclyl; or R7R8 = (un)substituted carbocyclic or heterocyclic ring; R32 = H, (hydroxy)alkyl, CN, acyl, carbamoyl, CHO, or alkoxycarbonyl; n = 0-2; or pharmaceutically acceptable salts, amides, esters, or stereoisomers thereof] were prepd. as cathepsin S inhibitors for the treatment of an allergic condition, including an atopic allergic conditions. For example, 1-methanesulfonylpiperidin-4-one (prepn. given) was condensed with morpholine in the presence of TsOH to give the enamine. Reaction with 4-CF3C6H4COCl, followed by cycloaddn. with H2NNH2, gave 5-methanesulfonyl-3-(4-trifluoromethylphenyl)-4,5,6,7-tetrahydro-1H-pyrazol[4,3-c]pyridine (72%). Alkylation with epichlorohydrin (35%) and addn. of 5-chloro-3-piperidin-4-yl-1H-indole (prepn. given) afforded II (88%). The latter inhibited recombinant human cathepsin S with IC50 of 0.07 .mu.M.

IT **400801-85-6P**, 5-Morpholin-4-yl-1H-pyrrolo[2,3-c]pyridine
400801-88-9P, Dimethyl-(1H-pyrrolo[3,2-c]pyridin-6-yl)-amine
400801-93-6P, 6-Morpholin-4-yl-1H-pyrrolo[3.2-c]pyridine
400801-97-0P, 6-Morpholin-4-yl-1H-pyrrolo[3.2-c]pyridine 5-oxide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of phenylpyrazolopyridine antiallergy agents from piperidinones, benzoyl chlorides, and hydrazine)

RN 400801-85-6 CAPLUS

CN 1H-Pyrrolo[2,3-c]pyridine, 5-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 400801-88-9 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridin-6-amine, N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 400801-93-6 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine, 6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 400801-97-0 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine, 6-(4-morpholinyl)-, 5-oxide (9CI) (CA INDEX NAME)



IT **271-34-1**, 1H-Pyrrolo[3,2-c]pyridine **271-63-6**, 1H-Pyrrolo[2,3-b]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of phenylpyrazolopyridine antiallergy agents from piperidinones, benzoyl chlorides, and hydrazine)
RN 271-34-1 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



L27 ANSWER 18 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:142709 CAPLUS
DN 136:200183
TI Substituted and/or fused pyrazoles, particularly indolylpiperidinylpropyl-substituted pyrazolopyridines, useful as cathepsin S inhibitors, and their pharmaceutical compositions and use as immunosuppressants
IN Cai, Hui; Edwards, James P.; Meduna, Steven P.; Pio, Barbara A.; Wei, Jianmei
PA Ortho McNeil Pharmaceutical, Inc., USA
SO PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002014317	A2	20020221	WO 2001-US25180	20010810
	WO 2002014317	A3	20020704		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001084823	A5	20020225	AU 2001-84823	20010810
	US 2002040019	A1	20020404	US 2001-927188	20010810
	US 6635633	B2	20031021		
	EP 1309592	A2	20030514	EP 2001-963912	20010810
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003225062	A1	20031204	US 2003-402694	20030328
	US 2003225063	A1	20031204	US 2003-402696	20030328
	US 2003229075	A1	20031211	US 2003-401486	20030328
PRAI	US 2000-225178P	P	20000814		
	US 2001-927188	A	20010810		
	WO 2001-US25180	W	20010810		

OS MARPAT 136:200183
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Substituted pyrazoles I, methods of manufg. them, compns. contg. them, and methods of using them to treat, for example, autoimmune diseases mediated by cathepsin S, are described [W, X, Y, Z = N, (un)substituted CH (0-3 of them may be N; or 1 can be N-oxide when other 3 .noteq. N); R = H, alkyl, cyano, hydroxyalkyl, acyl, CHO, alkoxycarbonyl, or (un)substituted carbamoyl; R1, R2 = H, alkyl; R3, R4 = H, alkyl, alkenyl, alkoxy, alkylthio, halo, or 4- to 7-membered carbo- or heterocyclyl; or R3R4 = atoms to form (un)substituted (un)satd. (non)arom. 5- to 7-membered carbo- or heterocyclic ring; Ar = (un)substituted mono- or bicyclic (hetero)aryl; n = 0-2; G = (un)substituted C3-6 alkanediyl or alkenediyl (substituents = OH, halo, oxo, aminoalkyl, etc.); Q = O, S, (un)substituted NH; including

stereoisomers, pharmaceutically acceptable salts, esters, and amides]. Claimed uses include treatment of lupus, rheumatoid arthritis, and particularly asthma, and inhibition of tissue transplant rejection. Approx. 70 individual compds. I were prepd. and/or claimed, with detailed prepns. given for 13 compds. For instance, 6-(morpholin-4-yl)-3-(piperidin-4-yl)-1H-pyrrolo[3,2-c]pyridine (prepd. in 5 steps) reacted with the corresponding epoxide (prepd. in several steps) to give title compd. II, a preferred compd. In an assay for inhibition of recombinant human cathepsin S in vitro, II had an IC50 of 0.02 .mu.M. Compd. III is another one of four specifically preferred compds.

IT **400801-85-6P**, 5-Morpholin-4-yl-1H-pyrrolo[2,3-c]pyridine
400801-88-9P, Dimethyl(1H-pyrrolo[3,2-c]pyridin-6-yl)amine
400801-93-6P, 6-Morpholin-4-yl-1H-pyrrolo[3,2-c]pyridine
400801-97-0P, 6-Morpholin-4-yl-1H-pyrrolo[3,2-c]pyridine 5-oxide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of indolylpiperidinylpropyl-substituted pyrazolopyridines and analogs as cathepsin S inhibitors)

RN 400801-85-6 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 5-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 400801-88-9 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridin-6-amine, N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 400801-93-6 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine, 6-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 400801-97-0 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine, 6-(4-morpholinyl)-, 5-oxide (9CI) (CA INDEX NAME)



IT **271-34-1**, 1H-Pyrrolo[3,2-c]pyridine **271-63-6**,
1H-Pyrrolo[2,3-b]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(precursor; prepn. of indolylpiperidinylpropyl-substituted pyrazolopyridines and analogs as cathepsin S inhibitors)
RN 271-34-1 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



L27 ANSWER 19 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:123005 CAPLUS
DN 136:167549
TI Preparation of variolin B derivatives as antitumor agents
IN Alvarez, Mercedes; Fernandez Bleda, David; Fernandez Puentes, Jose Luis
PA Universidad de Barcelona, Spain; Ruffles, Graham Keith
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002012240	A1	20020214	WO 2001-GB3517	20010803
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001076510	A5	20020218	AU 2001-76510	20010803
	EP 1307454	A1	20030507	EP 2001-954163	20010803
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001012920	A	20030701	BR 2001-12920	20010803
PRAI	GB 2000-19117	A	20000803		
	WO 2001-GB3517	W	20010803		

OS MARPAT 136:167549
GI



AB Variolin derivs. of formula I [R1 = arom. substituent; R2 = H, substituent, absent; R3 = oxo, substituent; R4 = H, substituent] are prepd. as antitumor agents. Thus, II was prepd. from III and 2-methylthio-4-trimethylstannylpyrimidine (prepns. given). The cytotoxicity of II against HT-29 was IC50 = 0.16 .mu.M.
IT **271-63-6**, 7-Azaindole **55052-28-3 122379-63-9**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of variolin B derivs. as antitumor agents)
RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 55052-28-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-chloro- (9CI) (CA INDEX NAME)



RN 122379-63-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-methoxy- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 20 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:809092 CAPLUS
DN 135:344505
TI Preparation of arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
IN Mewshaw, Richard E.; Zhou, Ping; Zhou, Dahui; Meagher, Kristin L.; Asselin, Magda; Evrard, Deborah A.; Gilbert, Adam M.
PA American Home Products Corp, USA
SO U.S., 62 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6313126	B1	20011106	US 1999-476254	19991230
	US 2002045628	A1	20020418	US 2001-969910	20011003
	US 6465482	B2	20021015		
PRAI	US 1999-155199P	P	19990107		
	US 1999-476254	A3	19991230		

OS MARPAT 135:344505
GI



I



II

AB Arylpiperazinyl-cyclohexyl indole derivs. of formula I [R1-R3 = H, halo, CF3, alkyl, alkoxy, MeSO2, or together can form a 5-7 membered carbocyclic or heterocyclic ring; R4 = H, halo, alkyl; R5 = H, alkyl, alkylaryl, aryl; R6 = H, halo, CF3, CN, carbamido, alkoxy; X1-X3, Y, Z = C, N] are prepd. which are useful for the treatment of serotonin-affected neurol. disorders such as depression and anxiety. Thus, II was prepd. from 4-(5-fluoro-1H-indol-3-yl)cyclohexanone and 1-(indol-4-yl)piperazine, and was shown to be active towards 5-HT1A receptors with Ki = 4.62 nM.

IT **282544-01-8P 282544-02-9P 282544-03-0P**
282544-04-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of arylpiperazinyl-cyclohexyl indole derivs. for treatment of depression)

RN 282544-01-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 3-[cis-4-[4-(1H-indol-4-yl)-1-piperazinyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 282544-02-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 3-[cis-4-[4-(1H-indol-4-yl)-1-piperazinyl]cyclohexyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



●3 HCl

RN 282544-03-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 3-[trans-4-[4-(1H-indol-4-yl)-1-piperazinyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 282544-04-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 3-[trans-4-[4-(1H-indol-4-yl)-1-piperazinyl]cyclohexyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



●3 HCl

IT **271-63-6**, 7-Azaindole
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of arylpiperazinyl-cyclohexyl indole derivs. for treatment of depression)
RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 21 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:635896 CAPLUS
DN 135:195552
TI Preparation of antiviral azaindole derivatives
IN Wang, Tao; Wallace, Owen B.; Zhang, Zhongxing; Meanwell, Nicholas A.; Bender, John A.
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001062255	A1	20010830	WO 2001-US2009	20010119
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1257276	A1	20021120	EP 2001-904970	20010119
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001008485	A	20030422	BR 2001-8485	20010119
	JP 2003523392	T2	20030805	JP 2001-561320	20010119
	NO 2002003981	A	20021017	NO 2002-3981	20020821
PRAI	US 2000-184004P	P	20000222		
	WO 2001-US2009	W	20010119		

OS MARPAT 135:195552
GI

Apps



I

AB The present invention is directed to a series of chem. entities that express HIV-1 inhibitory activities. Thus, azaindoles I [R1-R4 = H, alkyl, cycloalkyl, halo, etc.; R5 = Om and m = 0, 1; n = 1, 2; R6 = H, alkyl, alkenyl, etc.; R7-R14 = H, alkyl, cycloalkyl, etc.; Ar = (un)substituted Ph, 2-pyridyl, 2-furyl, etc.] were prepd. E.g., (R)-N-benzoyl-3-methyl-N'-[(7-azaindol-3-yl)oxoacetyl]piperazine was prepd.

IT **271-34-1**, 5-Azaindole **271-63-6**, 7-Azaindole
357263-40-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of antiviral azaindole derivs.)

RN 271-34-1 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 357263-40-2 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 4-methoxy- (9CI) (CA INDEX NAME)



IT **160590-40-9P**, 7-Methoxy-6-azaindole **357263-41-3P**
357263-42-4P 357263-43-5P 357263-44-6P
357263-48-0P 357263-68-4P 357263-69-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of antiviral azaindole derivs.)
RN 160590-40-9 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-methoxy- (9CI) (CA INDEX NAME)



RN 357263-41-3 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-chloro- (9CI) (CA INDEX NAME)



RN 357263-42-4 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine, 7-methyl- (9CI) (CA INDEX NAME)



RN 357263-43-5 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine, 5-chloro-7-methyl- (9CI) (CA INDEX NAME)



RN 357263-44-6 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine, 7-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 357263-48-0 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine, 7-chloro- (9CI) (CA INDEX NAME)



RN 357263-68-4 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 5,7-dibromo-4-methoxy- (9CI) (CA INDEX NAME)



RN 357263-69-5 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-chloro-4-fluoro- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 22 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:630893 CAPLUS
DN 135:195505
TI Preparation of azaheterocyclic sulfonamides as factor Xa inhibitors
IN Choi-Sledeski, Yong Mi; Pauls, Heinz W.; Barton, Jeffrey N.; Ewing, William R.; Green, Daniel M.; Becker, Michael R.; Gong, Yong; Levell, Julian
PA Aventis Pharma Deutschland Gmbh, Germany
SO U.S., 96 pp., Cont.-in-part of U.S. Ser. No. 90,492.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6281227	B1	20010828	US 1999-453307	19991202
	WO 9825611	A1	19980618	WO 1997-US22406	19971203
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 6602864	B1	20030805	US 1998-90492	19980603
	WO 9962904	A1	19991209	WO 1999-US12312	19990603
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	WO 2001039759	A2	20010607	WO 2000-EP11577	20001121
	WO 2001039759	A3	20020117		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002013310	A1	20020131	US 2001-918039	20010730
PRAI	US 1996-33159P	P	19961213		
	WO 1997-US22406	A2	19971203		
	US 1998-90492	A2	19980603		
	WO 1999-US12312	A2	19990603		
	US 1999-453307	A	19991202		

OS MARPAT 135:195505
GI



I



II

AB Title compds. [I; X = (CHR3)m; R = (un)substituted heteroaryl; R1, R2 = H, (un)substituted alkyl, alkenyl, aralkyl; R3 = H, OH, (un)substituted alkyl, aryl, heteroaryl; R4 = H, (un)substituted alkyl, aryl, aralkyl; R5, R6 = H; R5R6 = O; R7, R8 = H, (un)substituted alkyl, aryl, aralkyl, heteroaryl; R7R8 = O; R3R7 = alkylene; m = 0-3] were prepd. Thus, title compd. II was prepd. from 3-acetamido-4-methylbenzaldehyde, malonic acid, and 7-methoxy-2-naphthalenesulfonyl chloride in 10 steps. II had a Ki of 80 nM for inhibition of factor Xa.

IT **60290-21-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of azaheterocyclic sulfonamides as inhibitors of factor Xa)

RN 60290-21-3 CAPLUS

CN 1H-Pyrrolo[3,2-c]pyridine, 4-chloro- (9CI) (CA INDEX NAME)



IT **271-34-1P**, 1H-Pyrrolo[3,2-c]pyridine **65156-94-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of azaheterocyclic sulfonamides as inhibitors of factor Xa)

RN 271-34-1 CAPLUS

CN 1H-Pyrrolo[3,2-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 65156-94-7 CAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine, 5-chloro- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 23 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:545664 CAPLUS
DN 135:137514
TI Preparation and formulation heterocyclyl-alkanoic acids for pharmaceutical use as integrin .alpha.v receptor antagonists
IN Askew, Ben C.; Breslin, Michael J.; Duggan, Mark E.; Hutchinson, John H.; Meissner, Robert S.; Perkins, James J.; Steele, Thomas G.; Patane, Michael A.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 169 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001053262	A1	20010726	WO 2001-US1953	20010119
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1254116	A1	20021106	EP 2001-908643	20010119
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2003520271	T2	20030702	JP 2001-553266	20010119
	US 2001053853	A1	20011220	US 2001-767471	20010123
PRAI	US 2000-177792P	P	20000124		
	US 2000-230469P	P	20000906		
	WO 2001-US1953	W	20010119		

OS MARPAT 135:137514
GI



I

AB Heterocyclyl-alkanoic acids, such as X-(CH2)4-Y-CHR4CH2CO2R5 [X = nitrogen contg. heterocyclyl, such as pyridinyl, pyrimidinyl, azaindolyl, etc.; Y =

(CH2)2, CONR3; R3, R5 = H, alkyl; R4 = aryl or heteroaryl, such as Ph, naphthyl, furyl thienyl, imidazolyl, etc.] were prepd. as antagonists of the integrin receptors .alpha.v.beta.3 and/or .alpha..beta.5 and may be useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth. Thus, the trifluoroacetic acid salt of heterocyclyl-alkanoic acid I was prepd. via a multistep synthetic sequence starting from 2-methoxypyridine, Et acrylate, Et 4-pentenoate, and 6-chloro-2,4-diaminopyrimidine. The prepd. acids were tested for integrin .alpha.v.beta.3 and .alpha..beta.5 binding activity and bone resorption activity. Examples of pharmaceutical formulations of the heterocyclyl-alkanoic acids were also presented.

IT **271-63-6**, 1H-Pyrrolo[2,3-b]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. and formulation heterocyclyl-alkanoic acids for pharmaceutical use as integrin .alpha.v receptor antagonists)

RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



IT **55052-24-9P 351447-81-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and formulation heterocyclyl-alkanoic acids for pharmaceutical use as integrin .alpha.v receptor antagonists)

RN 55052-24-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 7-oxide (9CI) (CA INDEX NAME)



RN 351447-81-9 CAPLUS
CN 1-Decyn-5-one, 1-(1H-pyrrolo[2,3-b]pyridin-6-yl)- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 24 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:489395 CAPLUS
DN 135:92651
TI Preparation of azaindoles as protein kinase inhibitors
IN Cox, Paul Joseph; Majid, Tahir Nadeem; Lai, Justine Yeun Quai; Morley, Andrew David; Amendola, Shelley; Deprets, Stephanie; Edlin, Chris
PA Aventis Pharma Ltd., UK
SO PCT Int. Appl., 270 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001047922	A2	20010705	WO 2000-GB4993	20001227
	WO 2001047922	A3	20020117		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1263759	A2	20021211	EP 2000-985695	20001227
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2000017038	A	20030107	BR 2000-17038	20001227
	EE 200200343	A	20030616	EE 2002-343	20001227
	JP 2003519144	T2	20030617	JP 2001-549392	20001227
	BG 106836	A	20030430	BG 2002-106836	20020618
	NO 2002003032	A	20020621	NO 2002-3032	20020621
PRAI	GB 1999-30698	A	19991224		
	US 2000-215818P	P	20000705		
	WO 2000-GB4993	W	20001227		

OS MARPAT 135:92651
GI



I

AB The invention is directed to compns. contg. physiol. active compds. of general formula [I; wherein R1 is (un)substituted aryl or heteroaryl; R2 represents hydrogen, acyl, cyano, halo, lower alkenyl or lower alkyl optionally substituted by a substituent selected from cyano, heteroaryl, heterocycloalkyl, -Z1R8, -CONY3Y4,-CO2R8,-NY3Y4, -N(R6)COR7, -N(R6)CONY3Y4, -N(R6)CO2R7, -N(R6)SO2R7, -N(R6)SO2NY3Y4 and one or more halogen atoms; R3 represents hydrogen, aryl, cyano, halo, heteroaryl, lower alkyl, -CO2R5 or -CONY3Y4; and X1 represents N, CH, C-halo, C-CN, C-R7, C-NY3Y4, C-OH, C-Z2R7, C-CO2R5, C-CONY3Y4, C-N(R8)COR7, C-SO2NY3Y4,

C-N(R8)SO2R7, C-alkenyl, C-alkynyl or C-NO2; wherein R5 represents hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; R6 represents hydrogen or lower alkyl; R7 represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; R8 represents hydrogen or lower alkyl; represents; Y3 and Y4 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group -NY3Y4 may form a cyclic amine; Z1 represents O or S; Z2 represents O or S(O)n; n is zero or an integer 1 or 2] and their prodrugs, and pharmaceutically acceptable salts and solvates of such compds. and their prodrugs. These compds. have valuable pharmaceutical properties, in particular the ability to inhibit protein kinases, esp. Syk kinase, and are useful for the treatment of asthma, psoriasis, joint inflammation, and inflammatory bowel disease. Thus, a stirred soln. of diisopropylamine (59.9 mL) in THF (1,400 mL), at -15 .degree.C and under nitrogen, was treated with a soln. of n-butyllithium in hexanes (131 mL, 1.6 M) over 25 min at <-10.degree.. After stirring for 30 min the mixt. was treated with methylpyrazine (26.8 g) over 15 min, then stirred for 1 h and then treated with a soln. of 5-methoxy-1-methyl-1H-indole-3-carbonitrile (53 g) in THF (600 mL) over 1 h at <-10.degree., and the reaction mixt. was allowed to warm to room temp. over 2 h and then stood overnight to give, after workup and flash chromatog., 6-(5-Methoxy-1-methyl-1H-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine (19.4 g) as a gray solid. I showed IC50 of 10-100 nM against Syk kinase.

IT **55052-24-9P**, 1H-Pyrrolo[2,3-b]pyridine-7-oxide **55052-28-3P**
344327-11-3P, 1H-Pyrrolo[2,3-b]pyridine-4-carbonitrile
348640-54-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of azaindoles as protein kinase inhibitors)

RN 55052-24-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 7-oxide (9CI) (CA INDEX NAME)



RN 55052-28-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-chloro- (9CI) (CA INDEX NAME)



RN 344327-11-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine-4-carbonitrile (9CI) (CA INDEX NAME)



RN 348640-54-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-phenyl- (9CI) (CA INDEX NAME)



IT **271-63-6**, 7-Azaindole **83683-82-3**, 4-Nitro-1H-pyrrolo[2,3-b]pyridine **348640-06-2**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of azaindoles as protein kinase inhibitors)
RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 83683-82-3 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-nitro- (9CI) (CA INDEX NAME)



RN 348640-06-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 4-bromo- (9CI) (CA INDEX NAME)


Br
NH
N

L27 ANSWER 25 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:279453 CAPLUS
DN 134:295809
TI Preparation of polycyclic azaindole derivatives and their affinity for melatonin receptors
IN Guillaumet, Gerald; Viaud, Marie-Claude; Van De Poel, Herve; Delagrange, Philippe; Bennejean, Caroline; Renard, Pierre
PA Adir Et Compagnie, Fr.
SO Eur. Pat. Appl., 41 pp.
CODEN: EPXXDW
DT **Patent**
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1092717	A2	20010418	EP 2000-402832	20001013
	EP 1092717	A3	20011004		
	EP 1092717	B1	20030108		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	FR 2799757	A1	20010420	FR 1999-12900	19991015
	FR 2799757	B1	20011214		
	US 6495543	B1	20021217	US 2000-689578	20001012
	JP 2001114781	A2	20010424	JP 2000-314109	20001013
	CN 1293195	A	20010502	CN 2000-130473	20001013
	ZA 2000005667	A	20010515	ZA 2000-5667	20001013
	BR 2000004823	A	20010522	BR 2000-4823	20001013
	AT 230745	E	20030115	AT 2000-402832	20001013
	PT 1092717	T	20030430	PT 2000-402832	20001013
	ES 2189730	T3	20030716	ES 2000-402832	20001013
	NO 2000005200	A	20010417	NO 2000-5200	20001016
	US 2003105087	A1	20030605	US 2002-267303	20021009
	US 2003134847	A1	20030717	US 2002-267238	20021009
	US 6667304	B2	20031223		
PRAI	FR 1999-12900	A	19991015		
	US 2000-689578	A3	20001012		

OS MARPAT 134:295809
GI



I

AB The title compds. I [the N atom in the ring may be in any position in the ring; R1 = NRCR'(Z), halo, R, S(O)nR, etc.; A = C(Z)NRR', NRC(Z)R', etc.; B forms with an atom of N and an atom of C a ring; R2, R3 = H, alkyl, alkoxy, OH, R2R3 = oxo; R4, R5 = H, or form with two adjacent atoms in ring B an aryl or heteroaryl group; G1 = alkylene] were prepd. The affinity of I for melatonin receptors was detd. E.g., [2-(2-methoxy-6H-pyrido[2',3':4,5]pyrrolo[2,1-a]isoindol-11-

yl)ethyl]acetamide was prepd.
IT **271-63-6**, 7-Azaindole
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of polycyclic azaindole derivs. and their affinity for melatonin receptors)
RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



IT **17288-40-3P 183208-35-7P 183208-36-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of polycyclic azaindole derivs. and their affinity for melatonin receptors)
RN 17288-40-3 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine, 5-methoxy- (8CI, 9CI) (CA INDEX NAME)



RN 183208-35-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo- (9CI) (CA INDEX NAME)



RN 183208-36-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-methoxy- (9CI) (CA INDEX NAME)



L27 ANSWER 26 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:137215 CAPLUS
DN 134:178544
TI Preparation of azaindoles as 5-HT6 antagonists
IN Edwards, Louise; Slassi, Abdelmalik; Tehim, Ashok; Xin, Tao
PA NPS Allelix Corp., Can.
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012629	A1	20010222	WO 2000-IB1122	20000814
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1204662	A1	20020515	EP 2000-949846	20000814
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003507380	T2	20030225	JP 2001-517527	20000814
PRAI	US 1999-148343P	P	19990812		
	WO 2000-IB1122	W	20000814		

OS MARPAT 134:178544
GI



I



II



III



IV

AB Title compds. (I) [wherein R = a group of formula (II) or (III); one of A, B, D, or E = a N atom, the remainder are CH groups; R1 =SO2Ar, COAr,

CH2Ar, or Ar; R2, R3, and R4 = independently H or alkyl; n = 1-3; Z = C, CH, or N; Ar = (un)substituted aryl], e.g. indolizinyl, quinazolinyl, and pyridinyl derivs., were prepd. as serotonin 5-HT6 receptor antagonists. For instance, 5-azaindole, 1,2,3,5,6,8,8a-heptahydro-7-oxoindolizine, and pyrrolidine were refluxed in EtOH for 6 h to give 3-(1,2,3,5,8,8a-hexahydro-7-indolizinyl)-1H-5-azaindole (51.6%). Acylation with 2-chlorobenzoyl chloride gave IV (56.4%). I showed selectivity for the 5-HT6 receptor (> 90% inhibition for preferred compds.) compared to other serotonin receptors, e.g. 5-HT2A, 5-HT2C, and 5-HT7 (< 10% inhibition for preferred compds.). In addn., selected compds. of the invention reversed serotonin stimulation of adenyl cyclase and behaved as 5-HT6 receptor antagonists. I are useful in the treatment of schizophrenia (no data).

IT **271-29-4**, 6-Azaindole **271-34-1**, 5-Azaindole
271-63-6, 7-Azaindole **272-49-1**, 4-Azaindole
RL: RCT (Reactant); RACT (Reactant or reagent)
(starting material; prepn. of azaindoles as 5-HT6 receptor antagonists for the treatment of schizophrenia)

RN 271-29-4 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 271-34-1 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 272-49-1 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 27 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:131203 CAPLUS
DN 134:178543
TI Preparation of azaindoles as 5-HT6 receptor antagonists.
IN Edwards, Louise; Slassi, Abdelmalik; Tehim, Ashok; Xin, Tao
PA NPS Allelix Corp., Can.
SO U.S., 15 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6191141	B1	20010220	US 1999-373212	19990812
	US 2001049441	A1	20011206	US 2000-741815	20001222
PRAI	US 1999-373212	A3	19990812		

OS MARPAT 134:178543
GI



AB Title compds. [I; R = Q1, Q2; 1 of A, B, D, E = N, the remainder = CH; R1 = SO2Ar, COAr, CHAr, Ar; R2, R3, R4 = H, alkyl; dotted line = single or double bond, with the proviso that there is only 1 double bond in the ring at a time; n = 1-3; Z = C, CH, N, provided that when dotted line = double bond, Z = C and when dotted line = single bond, Z = CH, N; Ar = (substituted) aryl; when R = Q1, then R1 = SO2Ar], were prepd. Thus, 5-azaindole, 1,2,3,5,6,8,8a-heptahydro-7-oxoindolizine, and pyrrolidine were refluxed 6 h in EtOH to give 51.6% 3-(1,2,3,5,8,8a-hexahydro-7-indolizinyl)-1H-5-azaindole. Several I, for example 1-(2-naphthalenesulfonyl)-3-(octahydro-7-indolizinyl)-4-azaindole, gave >95% inhibition of binding of 3H-LSD to the 5-HT6 receptor.

IT **271-29-4**, 6-Azaindole **271-34-1**, 5-Azaindole
271-63-6, 7-Azaindole **272-49-1**, 4-Azaindole
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of azaindoles as 5-HT6 receptor antagonists)

RN 271-29-4 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 271-34-1 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 272-49-1 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 28 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:772631 CAPLUS
DN 133:335224
TI Disclosure of azaindole derivatives for the treatment of depression and methods for their preparation
IN Mewshaw, Richard Eric; Meagher, Kristin Lynne
PA American Home Products Corporation, USA
SO PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000064898	A1	20001102	WO 2000-US10628	20000420
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6337336	B1	20020108	US 2000-551134	20000417
	EP 1171439	A1	20020116	EP 2000-923540	20000420
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	BR 2000010693	A	20020205	BR 2000-10693	20000420
	JP 2002543079	T2	20021217	JP 2000-614250	20000420
PRAI	US 1999-296736	A	19990422		
	US 1999-219530P	P	19990422		
	WO 2000-US10628	W	20000420		

OS MARPAT 133:335224
GI



I



II

AB The title compds. I (R1 and R2 form a carbocyclic or heterocyclic ring of 5 to 7 atoms, wherein said ring may be satd. or unsatd.; X = H, CN, carbamoyl, halo or alkoxy) or pharmaceutically acceptable salts thereof and methods for their prepn. are disclosed. Thus, II was prepd. by substitution of 5-(2-chloroethoxy)-2,3-dihydrobenzo[1,4]dioxane with 3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[2,3-b]pyridine in anhyd. dimethylsulfoxide in the presence of triethylamine. The disclosed compds. are useful as agents in the treatment of diseases affected by disorders of the serotonin-affected neurol. systems, such as depression and anxiety. Bioassays showed that I are active toward 5-HT1A receptors, and generally elevate serotonin levels by inhibiting 5-HT transport.

IT **303751-52-2P 303751-57-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn of azaindole derivs. as antidepressants and anxiolytics)

RN 303751-52-2 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 3-[1,2,3,6-tetrahydro-1-[2-(1H-indol-4-yloxy)ethyl]-4-pyridinyl]- (9CI) (CA INDEX NAME)



RN 303751-57-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 3-[1,2,3,6-tetrahydro-1-[2-(1H-indol-4-yloxy)ethyl]-4-pyridinyl]-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 303751-52-2
CMF C22 H22 N4 O



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT **271-63-6**, 7-Azaindole
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn of azaindole derivs. as antidepressants and anxiolytics)

RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 29 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:688216 CAPLUS
DN 133:266726
TI Preparation of 3-(anilinomethylene)oxindoles and analogs as protein tyrosine kinase and protein serine/threonine kinase inhibitors
IN Glennon, Kimberley Caroline; Kuyper, Lee Frederick; Lackey, Karen Elizabeth; McNutt, Robert Walton, Jr.
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 189 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000056710	A1	20000928	WO 2000-US5057	20000228
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1165514	A1	20020102	EP 2000-913643	20000228
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	US 6350747	B1	20020226	US 2000-514528	20000228
	JP 2002540097	T2	20021126	JP 2000-606572	20000228
	US 6498176	B1	20021224	US 2001-914063	20010822
	US 2002099071	A1	20020725	US 2001-966318	20010927
PRAI	GB 1999-4933	A	19990304		
	US 2000-514528	A3	20000228		
	WO 2000-US5057	W	20000228		

OS MARPAT 133:266726
GI



I



II

AB The title compds. (I) [wherein X = N, CH, CCF3, or C(aliph.); Y, Z, A, and D = C or N, and the no. of N .ltoreq. 1; R1 = H, aliph., SH, hydroxy(aliph.), aryl(aliph.), cycloalkyl(aliph.), heterocyclyl(aliph.), (un)substituted NH2, CONH2, or SO2NH2, alkoxycarbonyl, halo, CN, or NO2; R2 = H, aliph., hydroxyimino aliph., alkoxy(carbonyl), hydroxyaliph., aryl(oxycarbonyl), heterocyclyl, (un)substituted CONH2, NH2, or SO2NH2, halo, OH, NO2, aliph. sulfonyl, etc.; or R1 and R2 are joined to form an (un)substituted fused heterocyclic ring; R3 = H, aliph., hydroxy(aliph.), (un)substituted NH2, CONH2, or SO2NH2, alkoxy, aryl(oxy), hydroxyaryl, (hydroxy)heterocyclyl, heterocyclyloxy, or halo; or R2 and R3 are joined to form an (un)substituted fused heterocyclic ring; R4 = SO3H, (aliph.)sulfonyl(aliph.), (un)substituted SO2NH2, NH2, CONH2, etc.; R5 = H; or R4 and R5 are joined to form an (un)substituted fused heterocyclic ring] were prepd. via std. synthetic methods and soln. phase library techniques as vascular endothelial growth factor receptor type 2 (VEGFR-2), cyclin dependent kinase 2 (CDK2), tyrosine kinase Tie-2 receptor, and colony-stimulating factor 1 receptor kinase (c-fms) inhibitors. For example, a mixt. of 8-dimethylaminomethylene-6,8-dihydro-1-thia-3,6-diaza-as-indacene-7-one (prepn. given) and 2-(4-aminophenyl)-3-methylpyrazolin-5-one in abs. EtOH was heated with stirring at 90.degree.C for 16 h to give (Z)-II (83%). In substrate phosphorylation assays, II inhibited VEGFR-2 and CDK2 with IC50 values of 1-10 .mu.M and 11-50 .mu.M, resp. I are useful as therapeutic agents in disease states alleviated by the inhibition or antagonism of protein kinase activated signalling pathways in general, and in particular in the pathol. processes which involve aberrant cellular proliferation, such as tumor growth, restenosis, atherosclerosis, and thrombosis. I are particularly useful for suppressing tumor growth by inhibiting tumor-related angiogenesis.

IT **271-63-6**, 7-Azaindole **55052-27-2**, 6-Chloro-7-azaindole
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of anilinomethylene oxindolones and analogs as protein tyrosine kinase and protein serine/threonine kinase inhibitors by alkylation and amination of oxindolones via std. or soln. phase library methods)

RN 271-63-6 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 55052-27-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 6-chloro- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 30 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:666732 CAPLUS
DN 133:252418
TI Preparation of anilinomethylene aza-oxindoles and analogs as protein tyrosine kinase and protein serine/threonine kinase inhibitors
IN Harris, Philip Anthony; Kuyper, Lee Frederick; Lackey, Karen Elizabeth; Veal, James Marvin
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 105 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000055159	A2	20000921	WO 2000-US5583	20000303
	WO 2000055159	A3	20011129		
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1180105	A2	20020220	EP 2000-917713	20000303
	EP 1180105	B1	20030514		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2003502280	T2	20030121	JP 2000-605588	20000303
	AT 240328	E	20030515	AT 2000-917713	20000303
	US 6624171	B1	20030923	US 2001-914393	20010828
PRAI	GB 1999-4995	A	19990304		
	WO 2000-US5583	W	20000303		

OS MARPAT 133:252418
GI



I



II

AB The title compds. (I) [wherein X = N, CH, CCF3, or C(aliph.); Y, Z, A, and D = C or N, and the no. of N .ltoreq. 1; R1 = H, aliph., SH, hydroxy(aliph.), aryl(aliph.), cycloalkyl(aliph.), heterocyclyl(aliph.), (un)substituted NH2, CONH2, or SO2NH2, alkoxycarbonyl, halo, CN, or NO2; R2 = H, aliph., hydroxyimino aliph., alkoxy(carbonyl), hydroxyaliph., aryl(oxycarbonyl), heterocyclyl, (un)substituted CONH2, NH2, or SO2NH2, halo, OH, NO2, aliph. sulfonyl, etc.; or R1 and R2 are joined to form an (un)substituted fused heterocyclic ring; R3 = H, aliph., hydroxy(aliph.), (un)substituted NH2, CONH2, or SO2NH2, alkoxy, aryl(oxy), hydroxyaryl, (hydroxy)heterocyclyl, heterocyclyloxy, or halo; or R2 and R3 are joined to form an (un)substituted fused heterocyclic ring; R4 = SO3H, (aliph.)sulfonyl(aliph.), (un)substituted SO2NH2, NH2, CONH2, etc.; R5 = H; or R4 and R5 are joined to form an (un)substituted fused heterocyclic ring] were prepd. via std. synthetic methods and soln. phase library techniques as cyclin dependent kinase 2 (CDK2), colony-stimulating factor 1 receptor kinase (c-fms), and vascular endothelial growth factor receptor type 2 (VEGFR-2) inhibitors. For example, 1,5-diazainden-2-one.bul.HBr was reacted with N,N-dimethylformamide-di-t-Bu acetal in DMF to give the 3-dimethylaminomethylene deriv., which was treated with sulfanilamide in EtOH with HCl to form (Z)-II. In substrate phosphorylation assays, II inhibited CDK2 and VEGFR-2 with IC50 values of 0.01-0.1 .mu.M and 1.0-10 .mu.M, resp. I are useful as therapeutic agents in disease states alleviated by the inhibition or antagonism of protein kinase activated signalling pathways in general, and in particular in the pathol. processes which involve aberrant cellular proliferation, such as tumor growth, restenosis, atherosclerosis, and thrombosis. I are particularly useful for the prevention of chemotherapy-induced alopecia.

IT **271-63-6**, 1H-Pyrrolo[2,3-b]pyridine **55052-27-2**, 6-Chloro-1H-pyrrolo[2,3-b]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of phenylaminomethylene aza-oxindolones as protein tyrosine kinase and protein serine/threonine kinase inhibitors by alkylation and amination of aza-oxindolones via std. or soln. phase library methods)

RN 271-63-6 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 55052-27-2 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 6-chloro- (9CI) (CA INDEX NAME)



L27 ANSWER 31 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:475638 CAPLUS
DN 133:105051
TI Preparation of arylpiperazinyl-cyclohexyl indoles for the treatment of depression
IN Mewshaw, Richard Eric; Zhou, Ping; Zhou, Dahui; Meagher, Kristin Lynne; Asselin, Magda; Evrard, Deborah Ann; Gilbert, Adam Matthew
PA American Home Products Corporation, USA
SO PCT Int. Appl., 182 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000040554	A1	20000713	WO 2000-US223	20000106
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000007424	A	20011009	BR 2000-7424	20000106
	EP 1147083	A1	20011024	EP 2000-903114	20000106
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002534411	T2	20021015	JP 2000-592263	20000106
	ZA 2001005190	A	20020923	ZA 2001-5190	20010622
	NO 2001003369	A	20010903	NO 2001-3369	20010706
PRAI	US 1999-226583	A	19990107		
	WO 2000-US223	W	20000106		

OS MARPAT 133:105051
GI



I



II

AB The title compds. [I; Ra, R1-R3 = H, halo, CF3, etc.; two adjacent of Ra and R1-3 together can form (un)substituted 5-7 membered carbocyclic or heterocyclic ring; R4 = H, halo, alkyl; R5 = H, alkyl, arylalkyl, aryl; R6 = H, halo, CF3, etc.; X1-X3 = each C or one of X1-X3 may be N; Y = CH, N; Z = C, N] and their pharmaceutically acceptable salts, useful for the treatment of serotonin-affected neurol. disorders, were prepd. E.g., a multi-step synthesis of cis-II and trans-II which showed Ki of 32.0 nM and 5.29 nM against 5-HT1A binding, resp., was given.

IT **282544-01-8P 282544-02-9P 282544-03-0P**
282544-04-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arylpiperazinyl-cyclohexyl indoles for the treatment of depression)

RN 282544-01-8 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 3-[cis-4-[4-(1H-indol-4-yl)-1-piperazinyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 282544-02-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 3-[cis-4-[4-(1H-indol-4-yl)-1-piperazinyl]cyclohexyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



●3 HCl

RN 282544-03-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 3-[trans-4-[4-(1H-indol-4-yl)-1-piperazinyl]cyclohexyl]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 282544-04-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 3-[trans-4-[4-(1H-indol-4-yl)-1-piperazinyl]cyclohexyl]-, trihydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.



●3 HCl

IT **271-63-6**, 7-Azaindole
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of arylpiperazinyl-cyclohexyl indoles for the treatment of depression)
RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 32 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:784099 CAPLUS
DN 132:22881
TI Sulfonic acid or sulfonylamino N-(heteroaralkyl)azaheterocyclic amides as inhibitors of factor Xa
IN Choi-Sledeski, Yong Mi; Pauls, Heinz W.; Barton, Jeffrey N.; Ewing, William R.; Green, Daniel M.; Becker, Michael R.; Gong, Yong; Levell, Julian
PA Rhone-Poulenc Rorer Pharmaceuticals Inc., USA
SO PCT Int. Appl., 202 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9962904	A1	19991209	WO 1999-US12312	19990603
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6602864	B1	20030805	US 1998-90492	19980603
	CA 2333994	AA	19991209	CA 1999-2333994	19990603
	AU 9943298	A1	19991220	AU 1999-43298	19990603
	AU 758642	B2	20030327		
	EP 1086099	A1	20010328	EP 1999-955266	19990603
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI				
	BR 9910899	A	20011009	BR 1999-10899	19990603
	JP 2002517393	T2	20020618	JP 2000-552115	19990603
	US 6281227	B1	20010828	US 1999-453307	19991202
	NO 2000005912	A	20010131	NO 2000-5912	20001122
	US 2002013310	A1	20020131	US 2001-918039	20010730
PRAI	US 1998-90492	A2	19980603		
	US 1996-33159P	P	19961213		
	WO 1997-US22406	A2	19971203		
	WO 1999-US12312	W	19990603		
	US 1999-453307	A3	19991202		

OS MARPAT 132:22881
GI



I



II

AB Aza heterocycles I [X = (CHR3)m; R = (un)substituted heteroaryl; R1, R2 = H, (un)substituted alkyl, alkenyl, aralkyl; R3 = H, OH, (un)substituted alkyl, aryl, heteroaryl; R4 = H, (un)substituted alkyl, aryl, aralkyl; R5, R6 = H; R5R6 = O; R7, R8 = H, (un)substituted alkyl, aryl, aralkyl, heteroaryl; R7R8 = O; R3R7 = alkylene; m = 0-3] were prepd. I are inhibitors of the activity of Factor Xa. Thus, the amide II was prepd. from 3-acetamido-4-methylbenzaldehyde, malonic acid, and 7-methoxy-2-naphthalenesulfonyl chloride in 10 steps. II had a Ki of 80 nM for inhibition of factor Xa.

IT **60290-21-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of azaheterocyclic sulfonamides as inhibitors of factor Xa)

RN 60290-21-3 CAPLUS

CN 1H-Pyrrolo[3,2-c]pyridine, 4-chloro- (9CI) (CA INDEX NAME)



IT **271-34-1P**, 1H-Pyrrolo[3,2-c]pyridine **65156-94-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of azaheterocyclic sulfonamides as inhibitors of factor Xa)

RN 271-34-1 CAPLUS

CN 1H-Pyrrolo[3,2-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 65156-94-7 CAPLUS

CN 1H-Pyrrolo[3,2-b]pyridine, 5-chloro- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 33 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:568893 CAPLUS
DN 129:209133
TI Luminescent compounds and methods of making and using same
IN Wang, Suning; Liu, Wang; Hassan, Abdi
PA Queen's University At Kingston, Can.
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9836035	A1	19980820	WO 1998-CA100	19980213
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6312835	B1	20011106	US 1998-22416	19980212
	AU 9859780	A1	19980908	AU 1998-59780	19980213
	US 2002028351	A1	20020307	US 2001-983050	20011018
	US 6500569	B2	20021231		
PRAI	US 1997-39688P	P	19970213		
	US 1997-44037P	P	19970530		
	US 1998-22416	XX	19980212		
	WO 1998-CA100	W	19980213		

OS MARPAT 129:209133
AB Heterocyclic organoaluminum and organoboron coordination complexes are described which are photoluminescent and/or electroluminescent, emitting intense blue light. Methods of synthesizing such compds., methods of producing photoluminescence and electroluminescence, methods of applying the compds. in thin films, and uses of the compds. of the invention in luminescent probes, electroluminescent displays and the like are also described.
IT **211997-61-4P 211997-65-8P 211997-66-9P**
RL: DEV (Device component use); IMF (Industrial manufacture); PRP (Properties); PREP (Preparation); USES (Uses)
(organoaluminum and organoboron luminescent complexes and methods of making and using them)
RN 211997-61-4 CAPLUS
CN Boron, diethyl(1H-pyrrolo[2,3-b]pyridinato-.kappa.N1)(1H-pyrrolo[2,3-b]pyridine-.kappa.N7)-, (T-4)- (9CI) (CA INDEX NAME)



RN 211997-65-8 CAPLUS
CN Boron, triphenyl(1H-pyrrolo[2,3-b]pyridine-.kappa.N7)-, (T-4)- (9CI) (CA INDEX NAME)



RN 211997-66-9 CAPLUS
CN Boron, triphenoxy(1H-pyrrolo[2,3-b]pyridine-.kappa.N7)-, (T-4)- (9CI) (CA INDEX NAME)



IT **271-63-6**, 7-Azaindole
RL: RCT (Reactant); RACT (Reactant or reagent)
(organoaluminum and organoboron luminescent complexes and methods of making and using them)
RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 34 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:402310 CAPLUS
DN 129:81744
TI Preparation of sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds as inhibitors of factor Xa
IN Choi-Sledeski, Yong Mi; Pauls, Henry W.; Barton, Jeffrey N.; Ewing, William R.; Green, Daniel M.; Becker, Michael R.; et al.
PA Rhone-Poulenc Rorer Pharmaceuticals Inc., USA; Choi-Sledeski, Yong Mi; Pauls, Henry W.; Barton, Jeffrey N.; Ewing, William R.; Green, Daniel M.
SO PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9825611	A1	19980618	WO 1997-US22406	19971203
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9855182	A1	19980703	AU 1998-55182	19971203
	AU 726637	B2	20001116		
	EP 944386	A1	19990929	EP 1997-951573	19971203
	EP 944386	B1	20020918		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
	CN 1244798	A	20000216	CN 1997-181387	19971203
	BR 9713921	A	20000321	BR 1997-13921	19971203
	JP 2001506630	T2	20010522	JP 1998-526844	19971203
	AP 1032	A	20011224	AP 1999-1552	19971203
	W: GH, KE, LS, MW, SD, SZ, UG, ZW				
	AT 224192	E	20021015	AT 1997-951573	19971203
	ES 2184145	T3	20030401	ES 1997-951573	19971203
	ZA 9711207	A	19980720	ZA 1997-11207	19971212
	US 6602864	B1	20030805	US 1998-90492	19980603
	NO 9902853	A	19990810	NO 1999-2853	19990611
	KR 2000057528	A	20000925	KR 1999-705236	19990611
	US 6281227	B1	20010828	US 1999-453307	19991202
	US 2002013310	A1	20020131	US 2001-918039	20010730
PRAI	US 1996-33159P	P	19961213		
	WO 1997-US22406	W	19971203		
	US 1998-90492	A2	19980603		
	WO 1999-US12312	A2	19990603		
	US 1999-453307	A3	19991202		

OS MARPAT 129:81744
GI



I



II

AB The compds. of formula [I; Ar1 = a bicyclic heteroaryl contg. .gtoreq.1 N atom; Z = alkenyl; R1 = H, (un)substituted alkyl, aralkyl, or heteroalkyl, hydroxyalkyl, carboxy alkyl, carbamoylalkyl, aminoalkyl, etc.; R2 = R3S(O)p, R3R4NS(O)p; R3 = (un)substituted alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, aralkenyl, heteroaralkenyl; or R1 and R3 taken together with N(O)p or NS(O)pNR4 through which R1 and R3 are linked from a 5 to 7 membered (un)substituted heterocyclyl; wherein p = 1, 2; R4 = (un)substituted alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, etc.; X1, X1a = H, (un)substituted alkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; or X and X1a are taken together to form oxo; X3 = H, OH, (un)substituted alkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl; or X3 or one of X1 and X1a taken together form a 4 to 7 membered cycloalkyl; X5, X5a, X5b = H, (un)substituted NH2, HONH, alkoxyamino, NHNH2, (un)substituted OH, CONH2 or SO2NH2, halo, cyano, NO2, etc.; one of X5, X5a, and X5a = H, HO or (H, optionally substituted lower alkyl, hydroxy, alkoxy, or amino)NH that substitutes the distal ring of Ar1 at a position alpha to a nitrogen thereof] herein exhibit useful pharmacol. activity and accordingly are incorporated into pharmaceutical compns. and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compds. of formula I, compns. contg. compds. of formula I, and their use, which are for treating a patient suffering from, or subject to, physiol. condition (disorder) which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa. The physiol. disorder is venous vasculature, arterial vasculature, abnormal thrombus formation, acute myocardial infarction, unstable angina, thromboembolism, acute vessel closure assocd. with thrombolytic therapy, percutaneous transluminal coronary angioplasty, transient ischemic attacks, stroke, intermittent claudication or bypass grafting of the coronary or peripheral arteries, vessel luminal narrowing,

restenosis post-coronary or venous angioplasty, maintenance of vascular access patency in long-term hemodialysis patients, pathol. thrombus formation occurring in the veins of the lower extremities following abdominal, knee and hip surgery, a risk of pulmonary thromboembolism, or disseminated systemic intravascular coagulopathy occurring in vascular systems during septic shock, certain viral infections and cancer. Thus, 3-(S)-amino-1-(6-amino-1-chloroisoquinolin-7-ylmethyl)pyrrolidin-2-one was coupled with 7-methoxynaphthalene-2-sulfonyl chloride followed by amination with ammonium acetate in PhOH at 115.degree. for 2 h gave the title compd., N-[N-(isoquinolinylmethyl)oxopyrrolidinyl]naphthalenesulfonamide (II.CF3CO2H). II.CF3CO2H in vitro inhibited factor Xa, thrombin, trypsin, tissue-plasminogen activator (t-PA), plasmin and activated protein C with Ki value of 80 nM.

IT **60290-21-3**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compds. as inhibitors of factor Xa)

RN 60290-21-3 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine, 4-chloro- (9CI) (CA INDEX NAME)



IT **271-34-1P**, 1H-Pyrrolo[3,2-c]pyridine **65156-94-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compds. as inhibitors of factor Xa)

RN 271-34-1 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 65156-94-7 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine, 5-chloro- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 35 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:41475 CAPLUS
DN 126:59864
TI Synthesis of azaindoles
IN Bishop, Brian Christopher; Cameron, Mark; Cottrell, Ian Frank; Hands, David
PA Merck Sharp & Dohme Limited, UK
SO Brit. UK Pat. Appl., 24 pp.
CODEN: BAXXDU
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2298199	A1	19960828	GB 1996-3374	19960216
	GB 2298198	A1	19960828	GB 1996-3065	19960214
	US 5681959	A	19971028	US 1996-604133	19960220
PRAI	GB 1995-3400		19950221		
	GB 1995-22015		19951027		

OS CASREACT 126:59864; MARPAT 126:59864
GI



I



II

AB The title compds. [I; Q = H, C1-6 alkyl, C2-6 alkenyl, etc.; one of X, Y, Z = N and the others = CH; R1 = H, (un)substituted C1-6 alkyl, C2-6 alkenyl; R5 = H, C1-6 alkyl, aryl] were prepd. by deprotonation of compd. II [R = CO(O)C1-6 alkyl, C(O)C1-6 alkyl] with an alkyllithium reagent followed by reaction of the deprotonation product with an amide R5C(O)NR6R7 (wherein R6 = C1-6 alkyl; R7 = C1-6 alkyl, C1-6 alkoxy, aryl) or an ester R5C(O)OR8 (R8 = C1-6 alkyl, arylC1-4alkyl, aryl) and reaction of the resulting intermediate with a concd. acid.

IT **185139-00-8P**
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of azaindoles)

RN 185139-00-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, rel-(2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 271-63-6
CMF C7 H6 N2



CM 2

CRN 133-37-9
CMF C4 H6 O6

Relative stereochemistry.



IT **271-29-4P**, 1H-Pyrrolo[2,3-c]pyridine **271-34-1P**, 1H-Pyrrolo[3,2-c]pyridine **271-63-6P**, 1H-Pyrrolo[2,3-b]pyridine **35965-27-6P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(synthesis of azaindoles)
RN 271-29-4 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 271-34-1 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 35965-27-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 271-63-6
CMF C7 H6 N2



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



L27 ANSWER 36 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:722512 CAPLUS
DN 126:59972
TI Preparation of 3-piperazinomethylpyrrolo[2,3-b]pyridines as dopamine D4 receptor antagonists
IN Baker, Raymond; Kulagowski, Janusz J.; Curtis, Neil R.; Leeson, Paul D.; Ridgill, Mark P.; Smith, Adrian L.
PA Merck, Sharp & Dohme Ltd., UK
SO U.S., 19 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5576319	A	19961119	US 1994-296574	19940826
PRAI	US 1994-296574		19940826		

OS MARPAT 126:59972
GI



I

AB Title compds.[I; R = H or alkyl; R1 = H, halo, alkyl, alkoxy, etc.; R2 = alkyl, alkoxy, (hetero)aryl(alkyl), etc.; R3-R5 = H, halo, hydrocarbyl, heterocyclyl, etc.] were prepd. as dopamine D4 receptor antagonists (no data). Thus, 1-phenylpiperazine was condensed with HCHO and 1H-pyrrolo[2,3-b]pyridine to give I (R = R1 = R3 = R4 = R5 = H, R2 = Ph).
IT **158985-07-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 3-piperazinomethylpyrrolo[2,3-b]pyridines as dopamine D4 receptor antagonists)
RN 158985-07-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 3-[[4-(1H-indol-5-yl)-1-piperazinyl]methyl]-(9CI) (CA INDEX NAME)



IT **271-63-6**, 1H-Pyrrolo[2,3-b]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of 3-piperazinomethylpyrrolo[2,3-b]pyridines as dopamine D4 receptor antagonists)
RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



L27 ANSWER 37 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:716270 CAPLUS
DN 126:8108
TI Preparation of pyrrolopyridines
IN Roduit, Jean-paul; Wellig, Alain; Armbruster, Erich
PA Lonza Ag, Switz.
SO PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DT **Patent**
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9632391	A1	19961017	WO 1996-EP1469	19960403
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
	AU 9656451	A1	19961030	AU 1996-56451	19960403
PRAI	CH 1995-1046		19950411		
	WO 1996-EP1469		19960403		

OS CASREACT 126:8108; MARPAT 126:8108
GI



I

AB Title compds. (e.g., I; R1 = H, Me, alkoxy, etc.) were prepd. by cyclization of, e.g., 2-amino-3-(substituted)ethylpyridines in the presence of a Cu chromite catalyst. Thus, 2-amino-3-ethylpyridine was passed over BaO-activated Cu chromite with H2O and NH3 at 680.degree. to give 45.5% pyrrolo[2,3-b]pyridine and byproducts.
IT **271-63-6P**, 1H-Pyrrolo[2,3-b]pyridine **824-51-1P**
183586-34-7P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of pyrrolopyridines)
RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 824-51-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 6-methyl- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 183586-34-7 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine, 6-methyl- (9CI) (CA INDEX NAME)



L27 ANSWER 38 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:685279 CAPLUS
DN 125:328699
TI Preparation of N-(pyrrolopyridylalkyl)alkanamides and analogs as melatonin receptor ligands
IN Viaud, Marie-Claude; Guillaumet, Gerald; Mazeas, Daniel; Vandepoel, Herve; Renard, Pierre; Pfeiffer, Bruno; Delagrange, Philippe
PA Adir Et Compagnie, Fr.
SO Eur. Pat. Appl., 61 pp.
CODEN: EPXXDW
DT **Patent**
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 737685	A1	19961016	EP 1996-400778	19960411
	EP 737685	B1	20000719		
	R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	FR 2732969	A1	19961018	FR 1995-4504	19950414
	FR 2732969	B1	19970516		
	AT 194839	E	20000815	AT 1996-400778	19960411
	PT 737685	T	20001031	PT 1996-96400778	19960411
	ES 2150642	T3	20001201	ES 1996-400778	19960411
	CA 2174033	AA	19961015	CA 1996-2174033	19960412
	CA 2174033	C	20010724		
	NO 9601457	A	19961015	NO 1996-1457	19960412
	ZA 9602934	A	19961017	ZA 1996-2934	19960412
	AU 9650629	A1	19961024	AU 1996-50629	19960412
	AU 700071	B2	19981217		
	CN 1139111	A	19970101	CN 1996-104624	19960412
	CN 1058967	B	20001129		
	US 5714495	A	19980203	US 1996-631234	19960412
	JP 08291172	A2	19961105	JP 1996-92428	19960415
PRAI	FR 1995-4504	A	19950414		

OS MARPAT 125:328699
GI



I



II

AB Title compds. [I; R1R2 = (un)substituted CH:CHCH:N, -CH:CHN:CH, -CH:NCH:CH, -N:CHCH:CH; R4 = H, halo, OH, alkoxyalkyl, etc.; R5 = Z1Z2R; R = H, (cyclo)alkyl, alkenyl, etc.; Z = O, S, (alkyl)imino, etc.; Z1 = alkylene; Z2 = NR6C(:X), NR6C(:X)NH, C(:X)NR6; R6 = H, alkyl, aryl(alkyl), etc.; X = O or S] were prepd. as melatonin receptor ligands (no data). Thus, pyrrolo[2,3-b]pyridine was converted in 11 steps to title compd. II.
IT **271-63-6**, 1H-Pyrrolo[2,3-b]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of N-(pyrrolopyridylalkyl)alkanamides and analogs as melatonin receptor ligands)

RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



IT **183208-35-7P 183208-36-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-(pyrrolopyridylalkyl)alkanamides and analogs as melatonin receptor ligands)
RN 183208-35-7 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-bromo- (9CI) (CA INDEX NAME)



RN 183208-36-8 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 5-methoxy- (9CI) (CA INDEX NAME)



L27 ANSWER 39 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:324692 CAPLUS
DN 122:105862
TI Preparation and formulation of azaindoles as ulcer inhibitors
IN Takahashi, Toshihiro; Horigome, Masato; Momose, Kenichi; Nagai, Shinji; Oshida, Norio; Sugita, Masanori; Katsuyama, Koichi; Suzuki, Chikako; Nakamaru, Koichi
PA Nisshin Flour Milling Co, Japan
SO Jpn. Kokai Tokkyo Koho, 18 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 06247967	A2	19940906	JP 1993-35268	19930224
	JP 3465827	B2	20031110		
PRAI	JP 1993-35268		19930224		

OS MARPAT 122:105862
GI



I



II

AB The title compds. I [R1 = aryl, etc.; R2 = H; R3 = H, alkyl, etc.; R4 = H, alkyl, alkoxy, etc.; R5 = H, alkoxy, etc.; X, Y, Z = N, C; provisos are given] are prepd. Azaindole deriv. II (prepn. given) in vitro at 10 .mu.g/mL gave 96.2% inhibition of H+, K+-ATPase.

IT **271-29-4P**, 1H-Pyrrolo[2,3-c]pyridine **271-34-1P**, 1H-Pyrrolo[3,2-c]pyridine **272-49-1P**, 1H-Pyrrolo[3,2-b]pyridine **17288-53-8P 160590-40-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of azaindoles as ulcer inhibitors)

RN 271-29-4 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 271-34-1 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 272-49-1 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 17288-53-8 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 5-methoxy- (8CI, 9CI) (CA INDEX NAME)



RN 160590-40-9 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 7-methoxy- (9CI) (CA INDEX NAME)



L27 ANSWER 40 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:700925 CAPLUS
DN 121:300925
TI Pyrrolo-pyridine derivatives
IN Baker, Raymond; Curtis, Neil Roy; Kulagowski, Janusz Jozef; Leeson, Paul David; Ridgill, Mark Peter; Smith, Adrian Leonard
PA Merck Sharp and Dohme Limited, UK
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9420497	A1	19940915	WO 1994-GB337	19940221
	W: BB, BG, BR, BY, CN, CZ, FI, HU, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ, VN				
	RW: BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	BR 9406128	A	19960227	BR 1994-6128	19940221
	HU 71799	A2	19960228	HU 1995-1871	19940221
	CN 1118598	A	19960313	CN 1994-191350	19940221
	CA 2116213	AA	19940902	CA 1994-2116213	19940222
	EP 623618	A2	19941109	EP 1994-200426	19940222
	EP 623618	A3	19970402		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5432177	A	19950711	US 1994-200113	19940222
	AU 9456470	A1	19940908	AU 1994-56470	19940228
	AU 674373	B2	19961219		
	ZA 9401368	A	19941028	ZA 1994-1368	19940228
	JP 06279442	A2	19941004	JP 1994-31241	19940301
	ZA 9405699	A	19950307	ZA 1994-5699	19940801
	US 5622950	A	19970422	US 1995-459993	19950602
	NO 9503406	A	19951031	NO 1995-3406	19950830
	FI 9504088	A	19950831	FI 1995-4088	19950831
	US 5712285	A	19980127	US 1996-626099	19960403
PRAI	GB 1993-4111		19930301		
	GB 1993-16275		19930805		
	WO 1994-GB337		19940221		
	US 1994-200113		19940222		
	US 1995-296574		19950826		

OS MARPAT 121:300925
GI



I

AB The 3-(1-piperazinylmethyl)-1H-pyrrolo[2,3-b]pyridines I (R = H, alkyl;

R1, R2 = alkyl, alkoxy, etc.; R3-R5 = H, halo, cyano, etc.) were disclosed for the treatment of psychotic disorders. I are antagonists of dopamine receptor subtypes within the brain and have a selective affinity for the dopamine D4 receptor subtype over other dopamine receptor subtypes; I are accordingly of benefit in the treatment and/or prevention of psychotic disorders such as schizophrenia while manifesting fewer side-effects than those assocd. with classical neuroleptic drugs (no pharmacol. test data were shown).

IT **271-63-6**, 1H-Pyrrolo[2,3-b]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of (piperazinylmethyl)pyrrolo[2,3-b]pyridines dopaminergic D4 antagonists)

RN 271-63-6 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



IT **158985-07-0P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (piperazinylmethyl)pyrrolo[2,3-b]pyridines dopaminergic D4 antagonists)

RN 158985-07-0 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 3-[[4-(1H-indol-5-yl)-1-piperazinyl]methyl]- (9CI) (CA INDEX NAME)



L27 ANSWER 41 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:700924 CAPLUS
DN 121:300924
TI preparation of pyrrolo[2,3-b]pyridines as dopaminergic antagonists
IN Baker, Raymond; Curtis, Neil Roy; Kulagowski, Janusz Jozef; Leeson, Paul David; Smith, Adrian Leonard; Ridgill, Mark Peter
PA Merck Sharp and Dohme Ltd., UK
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9420459	A2	19940915	WO 1994-GB384	19940225
	WO 9420459	A3	19941013		
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2156410	AA	19940915	CA 1994-2156410	19940225
	AU 9460422	A1	19940926	AU 1994-60422	19940225
	AU 679040	B2	19970619		
	EP 687267	A1	19951220	EP 1994-906978	19940225
	EP 687267	B1	19990901		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 09500357	T2	19970114	JP 1994-519698	19940225
	AT 184008	E	19990915	AT 1994-906978	19940225
	ES 2134929	T3	19991016	ES 1994-906978	19940225
	US 5700809	A	19971223	US 1995-513828	19950829
PRAI	GB 1993-4110		19930301		
	GB 1993-16260		19930805		
	WO 1994-GB384		19940225		

OS MARPAT 121:300924
GI



AB Pyrrolo[2,3-b]pyridines I (R = alkyl; Q = piperidinyl, benzimidazolyl, etc.; R3-R5 = H, halo, alkyl, etc.) were disclosed as ligands for dopamine receptor subtypes and for the treatment and/or prevention of disorders of the dopamine system, in particular schizophrenia. An example compd., 3-[(1,2,3,4-tetrahydro-2-isoquinolinyl)methyl]-1H-pyrrolo[2,3-b]pyridine (II) was prepd. Pharmacol. test data were not shown.

IT **158984-51-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrrolo[2,3-b]pyridines dopaminergic antagonists)
RN 158984-51-1 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 3-[[3,6-dihydro-4-(1H-indol-6-yl)-1(2H)-pyridinyl]methyl]- (9CI) (CA INDEX NAME)



IT **271-63-6**, 1H-Pyrrolo[2,3-b]pyridine
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of pyrrolo[2,3-b]pyridines dopaminergic antagonists)
RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



L27 ANSWER 42 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1989:407754 CAPLUS
DN 111:7754
TI Preparation of deazapurine nucleoside derivatives for use in nucleic acid sequence analysis and as antiviral agents.
IN Seela, Frank; Muth, Heinz Peter; Kaiser, Klaus; Bourgeois, Werner; Muehlegger, Klaus; Von der Eltz, Herbert; Batz, Hans Georg
PA Boehringer Mannheim G.m.b.H., Fed. Rep. Ger.
SO Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DT **Patent**
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 286028	A2	19881012	EP 1988-105277	19880331
	EP 286028	A3	19900530		
	EP 286028	B1	19950628		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	DE 3739366	A1	19881027	DE 1987-3739366	19871120
	ES 2076146	T3	19951101	ES 1988-105277	19880331
	DK 8801946	A	19881011	DK 1988-1946	19880408
	AU 8814398	A1	19881013	AU 1988-14398	19880408
	AU 597483	B2	19900531		
	CN 88102038	A	19881026	CN 1988-102038	19880408
	JP 63275598	A2	19881114	JP 1988-85533	19880408
	JP 06062663	B4	19940817		
	HU 46703	A2	19881128	HU 1988-1786	19880408
	HU 199871	B	19900328		
	ZA 8802446	A	19881228	ZA 1988-2446	19880408
	DD 269854	A5	19890712	DD 1988-314564	19880408
	CA 1311201	A1	19921208	CA 1988-563635	19880408
	JP 07048396	A2	19950221	JP 1994-63020	19940331
PRAI	DE 1987-3712280	A	19870410		
	DE 1987-3739366	A	19871120		

OS MARPAT 111:7754
GI



AB The title compds. [I; X = N, CH; W = N, CR4; R1-R4 = H, halo, alkyl, OH,

SH, etc.; R5 = H, OH; Y = H, monophosphate, diphosphate, or triphosphate residue; R6, R7 = H, halo, cyano, amino, etc.], useful as antiviral agents and agents for DNA sequencing, were prepd. from heterocycles II and furanoses III (R8 = protecting group, R9, R10 = H, N3, protected OH, Z = reactive group). 2-Amino-7-deaza-2',3'-dideoxy-9-.beta.-ribofuranosylpurine-6-one was prepd. in 4 steps via phenoxythiocarbonylation of 2-[(4,4'-dimethoxytriphenylmethyl)amino]-7-deaza-2'-deoxy-5'-O-(4,4'-dimethoxytriphenylmethyl)-9-.beta.-D-ribofuranosylpurine-6-one and redn. of the resulting 3'-O-(phenoxythiocarbonyl) deriv. with Bu3SnH. Compared with 2',3'-dideoxyadenosine, 6-amino-8-aza-7-deaza-2',3'-dideoxy-9-.beta.-D-ribofuranosylpurine was more resistant to hydrolysis at 25.degree. as measured by the decrease in UV absorption at 258 nm.

IT **271-34-1**, 3,7-Dideazapurine **67139-79-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in prepn. of antiviral deazapurine nucleosides)

RN 271-34-1 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 67139-79-1 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine, 4,6-dichloro- (9CI) (CA INDEX NAME)



L27 ANSWER 43 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1985:36759 CAPLUS
DN 102:36759
TI Photoresist composition
PA Hitachi Chemical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 59046642	A2	19840316	JP 1982-157180	19820909
PRAI JP 1982-157180		19820909		

AB A photoresist compn. contains (1) .gtoreq.1 compd. selected from monoazaindoles, (2) a phosphoric acid deriv. having photopolymg. unsatn., (3) a photopolymg. compd. having .gtoreq.1 terminal ethylene group, (4) a thermoplastic org. polymer, and (5) a sensitizer or a sensitizer system for the polymn. of (2) and (3) activated by high-energy radiation. The photoresist compn. is highly adhesive to substrates and useful in manuf. of soldering masks. Thus, a mixt. of 2-hydroxyethyl acrylate 1856, PhMe 300, and p-methoxyphenol 0.3 wt. part was added to a stirred mixt. of trimethylhexamethylene diisocyanate 1680, PhMe 300, and dibutyltin dilaurate 1 wt. part and heated up to 80.degree. during 5 h. MeOH 20 wt. parts was then added and the mixt. was stirred for 1 h. Removal of the solvents gave a viscous resin product. A resin compn. was prepd. by mixing the above resin product 50 kg with acrylonitrile-acrylic acid-Me acrylate-Me methacrylate copolymer (5:2:10:83) 50, benzophenone 2.7, Michler's ketone 0.3, p-methoxyphenol 0.02, Victoria Pure Blue 0.05, PhMe 50, and MeCOEt 50 kg. Then 7-azaindole 0.01 and a methacryl group-contg. phosphoric acid deriv. (Phosmer M from Yushiseihin Co.) 0.01 kg were added to the above resin compn. 50 kg, coated on a poly(ethylene terephthalate) film support to form a 75 .mu. layer, covered with a 25 .mu. polyethylene protective film, bonded to a Cu-laminated substrate after peeling off the protective film, patternwise exposed to UV, heated at 80.degree. for 5 min, the film support removed, spray-developed using 1,1,1-trichloroethane, posttreated by UV irradn., and heated. The obtained material was dipped into a molten solder, and the soldered pattern showed no failure.

IT **271-63-6 272-49-1**
RL: USES (Uses)
(photoresist compns. contg. acryl group-contg. phosphoric acid deriv., photopolymg. monomers and thermoplastic copolymer and, for soldering masks)

RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 272-49-1 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L27 ANSWER 44 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1982:13663 CAPLUS
DN 96:13663
TI Photo resist compositions
PA Asahi Chemical Industry Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT **Patent**
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 56067844	A2	19810608	JP 1979-143250	19791107
	JP 57049894	B4	19821025		
PRAI	JP 1979-143250		19791107		

AB Photoresist compns. contain (1) unsatd. compds. having .gtoreq.2 end ethylenic groups, (2) photopolymn. initiators, and (3) a monoazaindole or its deriv. Thus, poly(vinyl cinnamate) (mol. wt. 5000) 60, triethylene glycol diacetate 5, benzophenone 3, 4,4'-bis(diethylamino)benzophenone 1.5, Malachite Green 1, p-MeOC6H4OH 0.03, and 4-azaindole 1 g were mixed in MeCOEt to give a photoresist compn. The resist layer showed excellent adhesion on Cu laminated resin plates.

IT **271-63-6 272-49-1**
RL: TEM (Technical or engineered material use); USES (Uses)
(photoresist compns. contg.)

RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 272-49-1 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



L27 ANSWER 45 OF 45 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1966:43743 CAPLUS
DN 64:43743
OREF 64:8152h,8153a-e
TI Pyrrole derivatives
PA Sterling Drug Inc.
SO 29 pp.
DT **Patent**
LA Unavailable
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	NL 6414916		19650624	NL	
PRAI	US		19631223		

GI For diagram(s), see printed CA Issue.

AB The title compds. (I), in which Ar is aromatic fused 1,2 to a pyrrole ring, R1 is H, alkyl, or Ph, and R2 is H or alkyl, were prepd. by heating N-(.omicron.-alkylaryl)-N'-phenyl-N'-methylamidine (II) with PhMeNNa (III) in excess PhMeNH (IV) at 180-300.degree.. The amidines (II) were obtained by treatment of an Et alkylarylimidate (V) with IV. Treatment of II with III and IV gave I directly. The required V were prepd. by treatment of an o-alkylarylamine with an ortho ester. Thus, a mixt. of 108 g. .omicron.-toluidine (VI), 2 g. VI.HCl, and 222 g. HC(OEt)3 was heated under a column from 88-160.degree., and 112 ml. EtOH distd. during 1.5 hrs. The mixt. was distd. in vacuo to give 79 g. HC(OEt)3, and 146 g. Et (2-methylphenyl)formimidate V (R1 = H, R2 = H, Ar = 1,2-benzo) (VII), b15 110.degree., n25D 1.5195. Other V were prepd. similarly (R1 CH2Ar, R2, and b.p. given): 3-methyl-2-pyridyl, H, b14 107-9.degree.; 2,4-MeMeOC6H3, H, b0.3 85-94.degree.; 2,6-dimethyl-3-pyridyl, H, b20 133-5.degree.; 3-methyl-4-pyridyl, H, b27 141-7.degree.. A mixt. of 164 g. VII and 216 g. IV was heated at 100.degree. under 20 mm. 15 hrs., heated to 400.degree., and a fraction, b19 120.degree., distd. during 4 hrs. The residue was poured into 100 ml. iso-PrOAc, cooled, and 60 g. N-(2-methylphenyl)-N'-methyl-N'-phenylformamidine II (R1 = H, Ar = Ph, R2 = H) (VIII), m. 98-100.degree., collected. The filtrate was evapd., the residue treated with 47 g. HOAc at 105-180.degree., the AcOH evapd., and the residue recrystd. from iso-PrOAc to give 76 g. VIII. Other II were prepd. similarly (R1CH2Ar and R2 given): 2-MeC6H4, H, m. 98-100.degree.; 3-methyl-2-pyridyl, H, b0.5 148-55.degree., m. 68-9.degree.; 2,4-MeMeOC6H3, H, b0.5 168-76.degree.; 2,6-dimethyl-3-pyridyl, H, b0.5 156-61.degree., n25D 1.6336. Alternatively, II were prepd. by reaction of PhMeNCHO (IX) with POCl3, followed by treatment with VII. Thus, a mixt. of 107 g. IV and 57.6 g. HCO2H was heated on a water bath 18 hrs., cooled, dild. with H2O, extd. with Et2O, and the exts. evapd. to to give 117 g. IX, b8 116-21.degree.. To a soln. of 107 g. IX in 150 ml. benzene was added 59 g. POCl3 in 150 ml. benzene, the mixt. stirred 6 hrs. and treated with 93.2 g. 2,6-dimethylaniline in 150 ml. benzene during 30 min. at 35-40.degree.. The mixt. was stirred 5 hrs., and poured into a mixt. of 170 ml. 35% NaOH, and 11. ice-H2O, the layers sepd., and the aq. phase extd. with CHCl3. The combined org. layers were dried over K2CO3 and evapd., the residue distd., and the fraction, b0.3 147-65.degree., crystd. from pentane to give N-(2,6-dimethyl-phenyl-N'-methyl-N'-phenylformamidine, II (R1 = H, Ar = 6-MeC6H4, R2 = H), m. 47-9.degree.. Other II were prepd. similarly (R1, Ar, and R2 given): H, 5-MeC6H4, H, b0.3, 165-73.degree., m. 78-80.degree.; H, Ph, H, m. 95-100.degree.; H, 4-chlorophenyl, H, m. 60-2.degree.. A mixt. of 19.5 g. NaNH2 and 108 ml. IV was refluxed 30 min., 100 ml. mineral oil added, the mixt. heated at 290.degree. with continuous removal of excess IV, and 56 g. VIII added to

the residue. The mixt. was stirred at 300.degree. 35 min. and cooled, the oil decanted, the residue covered with Et2O, and Na salts decompd. with 100 ml. H2O with cooling. The Et2O layer was sepd. and evapd. and the residue distd. to give 22.3 g. indole I (R1 = R2 = H, Ar = 1,2-C6H4), b22 131-7.degree.. Other I were prepd. similarly: 7-methylindole, b0.3 83-6.degree., m. 76-83.degree.; 6-methylindole, b0.5 79-82.5.degree., n25D 1.5824; 7-azaindole, b0.1 90-104.degree., m. 101-5.degree.; 5-methyl-4-azaindole, m. 205-7.degree.; 5-azaindole, b0.2 110-32.degree., m. 109-11.degree..

IT **271-34-1**, 1H-Pyrrolo[3,2-c]pyridine **271-63-6**, 1H-Pyrrolo[2,3-b]pyridine **4943-67-3**, 1H-Pyrrolo[3,2-b]pyridine, 5-methyl-
(prepn. of)

RN 271-34-1 CAPLUS
CN 1H-Pyrrolo[3,2-c]pyridine (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)



RN 271-63-6 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 4943-67-3 CAPLUS
CN 1H-Pyrrolo[3,2-b]pyridine, 5-methyl- (7CI, 8CI, 9CI) (CA INDEX NAME)



```
=> d his

     (FILE 'HOME' ENTERED AT 12:26:54 ON 29 DEC 2003)

     FILE 'REGISTRY' ENTERED AT 12:27:07 ON 29 DEC 2003
L1             STRUCTURE UPLOADED
L2           8 S L1
L3             SCREEN 1993
L4             STRUCTURE UPLOADED
L5             QUE L4 AND L3
L6           3 S L5
L7           0 S NC5-NC4/ES
L8       59638 S NC4-NC5/ES
L9          36 S L1  SUB=L8 SAM
L10        656 S L1  SUB=L8 FUL

     FILE 'CAPLUS' ENTERED AT 12:38:48 ON 29 DEC 2003
L11        793 S L10
L12        ANALYZE L11 1- RN HIT :     633 TERMS

     FILE 'REGISTRY' ENTERED AT 12:39:55 ON 29 DEC 2003
L13          1 S 271-63-6/RN
L14        655 S L11 NOT L13

     FILE 'CAPLUS' ENTERED AT 12:40:32 ON 29 DEC 2003
L15        419 S L14
L16        137 S L15 AND L13

     FILE 'REGISTRY' ENTERED AT 12:42:26 ON 29 DEC 2003
L17         98 S 271-?/RN
L18        606 S L10 AND PYRROLO?
L19    1720701 S PYRID?
L20        605 S L18 AND L19
L21          3 S L17 AND L20
L22        602 S L20 NOT L21

     FILE 'CAPLUS' ENTERED AT 12:44:21 ON 29 DEC 2003
L23        345 S L22
L24        574 S L21
L25        139 S L24 AND PATENT/DT
L26        136 S L23 AND PATENT/DT
L27         45 S L25 AND L26

=> log h
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   215.07     421.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -29.30     -29.30

 SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:55:23 ON 29 DEC 2003
```